

1 **A vision for safer food contact materials: public health concerns as**
2 **drivers for improved testing**

3 Jane Muncke^{a*}, Anna-Maria Andersson^b, Thomas Backhaus^c, Scott M.
4 Belcher^d, Justin M. Boucher^a, Bethanie Carney Almroth^c, Terrence J.
5 Collins^e, Birgit Geueke^a, Ksenia J. Groh^f, Jerrold J. Heindel^g, Frank A. von
6 Hippel^h, Juliette Leglerⁱ, Maricel V. Maffini^j, Olwenn V. Martin^k, John
7 Peterson Myers^{e,l}, Angel Nadal^m, Cristina Nerinⁿ, Ana M. Soto^o, Leonardo
8 Trasande^p, Laura N. Vandenberg^q, Martin Wagner^r, Lisa Zimmermann^a, R.
9 Thomas Zoeller^q and Martin Scheringer^{s*}

10 *^aFood Packaging Forum Foundation, Zurich, Switzerland; ^bDept. of Growth and*
11 *Reproduction, Rigshospitalet and Centre for Research and Research Training in Male*
12 *Reproduction and Child Health (EDMaRC), Copenhagen University Hospital –*
13 *Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark; ^cDept of Biological and*
14 *Environmental Sciences, University of Gothenburg, Sweden; ^dDept. of Biological*
15 *Sciences, North Carolina State University, Raleigh, NC, USA; ^eDept. of Chemistry,*
16 *Carnegie Mellon University, PA, USA; ^fDepartment of Environmental Toxicology,*
17 *Eawag, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf,*
18 *Switzerland; ^gHealthy Environment and Endocrine Disruptor Strategies, Durham, NC,*
19 *USA; ^hMel & Enid Zuckerman College of Public Health, University of Arizona, AZ,*
20 *USA; ⁱDept. of Population Health Sciences, Faculty of Veterinary Medicine, University*
21 *of Utrecht, Netherlands; ^jIndependent consultant, Frederick, MD, USA; ^kPlastic Waste*
22 *Innovation Hub, Department of Arts and Science, University College London, England,*
23 *UK; ^lEnvironmental Health Sciences, Charlottesville, VA, USA; ^mIDiBE and*
24 *CIBERDEM, Miguel Hernández University of Elche, Alicante, Spain; ⁿDept. of*
25 *Analytical Chemistry, I3A, University of Zaragoza, Zaragoza, Spain; ^oDepartment of*
26 *Immunology, Tufts University School of Medicine, Boston, MA, USA and Centre*
27 *Cavaillès, Ecole Normale Supérieure, Paris, France; ^pCollege of Global Public Health*
28 *and Grossman School of Medicine and Wagner School of Public Service, New York*
29 *University, New York, NY, USA; ^qDepartment of Environmental Health Sciences,*
30 *School of Public Health & Health Sciences, University of Massachusetts Amherst,*
31 *Amherst, MA, USA; ^rDept. of Biology, Faculty of Natural Sciences, Norwegian*

32 *University of Science and Technology, Trondheim, Norway; ^sEnvironmental Chemistry*
33 *and Modelling, RECETOX, Masaryk University, Brno, Czech Republic and Department*
34 *of Environmental System Sciences, ETH Zurich, Switzerland*

35 *corresponding authors: jane.muncke@fp-forum.org; scheringer@usys.ethz.ch

36

37 **Abbreviations**

38 AOP Adverse Outcome Pathway

39 BPA bisphenol A

40 CVD Cardiovascular Disease

41 FCC Food Contact Chemical

42 NCD Non-Communicable Disease

43 NIAS Non-Intentionally Added Substance

44 PFAS Per- and polyfluoroalkyl Substances

45 PFOA perfluorooctanoic acid

46 SCOD Six Clusters of Disease

47

48 **A vision for safer food contact materials: public health concerns as**
49 **drivers for improved testing**

50 Food contact materials (FCMs) and food contact articles are ubiquitous in today's
51 globalized food system. Chemicals migrate from FCMs into foodstuffs, so called
52 food contact chemicals (FCCs), but current regulatory requirements do not
53 sufficiently protect public health from hazardous FCCs because only individual
54 substances used to make FCMs are tested and mostly only for genotoxicity while
55 endocrine disruption and other hazard properties are disregarded. Indeed, FCMs
56 are a known source of a wide range of hazardous chemicals, and they likely
57 contribute to highly prevalent non-communicable diseases. FCMs can also
58 include non-intentionally added substances (NIAS), which often are unknown
59 and therefore not subject to risk assessment. To address these important
60 shortcomings, we outline how the safety of FCMs may be improved by (1)
61 testing the overall migrate, including (unknown) NIAS, of finished food contact
62 articles, and (2) expanding toxicological testing beyond genotoxicity to multiple
63 endpoints associated with non-communicable diseases relevant to human health.
64 To identify mechanistic endpoints for testing, we group chronic health outcomes
65 associated with chemical exposure into Six Clusters of Disease (SCOD) and we
66 propose that finished food contact articles should be tested for their impacts on
67 these SCOD. Research should focus on developing robust, relevant, and sensitive
68 *in-vitro* assays based on mechanistic information linked to the SCOD, e.g.,
69 through Adverse Outcome Pathways (AOPs) or Key Characteristics of Toxicants.
70 Implementing this vision will improve prevention of chronic diseases that are
71 associated with hazardous chemical exposures, including from FCMs.

72 **Keywords:** food packaging; hazard assessment; chronic disease; chemical safety

73 **1. Introduction**

74 In today's globalized food system, food contact materials (FCMs) and food
75 contact articles (Fig. 1) such as food packaging, tableware, and food processing
76 equipment are ubiquitous, especially those made of plastic (Chakori et al. 2021; Poças
77 et al. 2009). This increases exposures to food contact chemicals (FCCs) migrating from
78 FCMs (Biryol et al. 2017; Koch and Calafat 2009; Qian et al. 2018). This widespread,
79 continuous exposure to a wide range of synthetic chemicals requires a more stringent
80 safety assessment of FCMs than the current approaches used in low-, middle- and high-
81 income countries (Neltner et al. 2013a; Maffini et al. 2013; Alger et al. 2013; Grob et al.
82 2006; Muncke et al. 2017).

83 [Figure 1 near here]

84 FCMs have been studied for over 50 years and are a known source of chemicals
85 that migrate into foodstuffs (Castle et al. 1989; Bradley et al. 2008; Dionisi and Oldring
86 2002; Jickells et al. 1993; Sanchis, Yusà, and Coscollà 2017; Nerin and Asensio 2007;
87 Geueke et al. 2022; Tsochatzis et al. 2021; Oldring et al. 2014). Numerous FCCs, either
88 intentionally used in the manufacture of FCMs or non-intentionally added substances
89 (NIAS) that are present in the finished food contact article and that migrate into
90 foodstuffs (Nerin et al. 2013; Qian et al. 2018; Tisler and Christensen 2022), are known
91 to be hazardous and implicated with adverse human health impacts (Zimmermann et al.
92 2022; Groh et al. 2021; Van Bossuyt et al. 2019, 2016; Souton et al. 2017; Bengtstrom
93 et al. 2016; Symeonides et al. 2021).

94 However, the current approach to chemical risk assessment for FCMs is largely
95 focused on assessing genotoxicity of single substances used to manufacture FCMs and
96 therefore fails to account for other highly relevant mechanisms of toxicity that are of
97 equal concern as genotoxicity (Muncke et al. 2017) and, what is more, the current

98 approach does not assess NIAS that also migrate from FCMs (Fig. 2) (Muncke et al.
99 2020; Geueke et al. 2022). Addressing both issues, the limited scope of toxicity testing
100 as well as the lack of testing for all migrating FCCs, is necessary to protect public
101 health, and it can be done in a cost-efficient way.

102 [Figure 2 near here]

103 Indeed, non-cancer non-communicable diseases (NCDs) of increasing
104 prevalence in the global human population have been associated with several widely
105 used FCCs, such as bisphenol A (BPA), bisphenol F (BPF), perchlorate, and di(2-ethyl
106 hexyl) phthalate (DEHP), to name a few. Given that humans are in daily contact with
107 FCMs, those materials are likely a relevant exposure source of hazardous chemicals that
108 contribute to various NCDs.

109 In this article, we outline an improved assessment scheme for hazard
110 identification of FCCs that captures all exposure-relevant chemicals (known as the
111 *overall migrate*, i.e., all chemicals migrating as a mixture from finished food contact
112 articles into foodstuffs) including (unknown) NIAS, and we present a vision for
113 assessing the safety of FCMs that addresses biological effects linked to the most
114 prevalent NCDs (Muncke 2021; Zare Jeddi et al. 2021). These include heart disease,
115 stroke, cancer, diabetes, reproductive disorders, immunological disorders, and several
116 neurological conditions. We provide guidance on research and policy actions that
117 should be developed to protect the public from avoidable chronic chemical exposures
118 originating from FCMs and finished food contact articles.

119 **2. Problem set-up: Shortcomings of the current approach**

120 ***2.1 Non-communicable diseases are increasingly prevalent and associated with***
121 ***chemical exposures***

122 NCDs are a significant contributor to global mortality (WHO 2018). However,
123 the impact of NCDs is far greater than mortality alone, especially in low- and middle-
124 income countries where health care is often limited compared to high-income countries.
125 Both mortality and morbidity of selected NCDs have increased substantially over the
126 last 30 years. Premature deaths (<70 years) are primarily associated with cardiovascular
127 disease (17.7 million deaths per year, accounting for 45% of all NCD deaths), cancer
128 (8.8 million deaths per year, 22% of all NCD deaths), chronic respiratory disease (3.9
129 million deaths per year, 10% of all NCD deaths) and diabetes (1.6 million deaths per
130 year, 4% of all NCD deaths) (WHO 2018). Expressed in Disability-Adjusted Life
131 Years, cardiovascular diseases have increased by a factor of 1.4 from 1990 to 2017,
132 neoplasms by a factor of 1.5, and diabetes, urogenital, blood and endocrine diseases by
133 a factor of 1.6 (from 1990 to 2016) (Roser, Ritchie, and Spooner 2021) (Fig. S1).
134 Furthermore, among reproductive-age women and men, infertility is now the most
135 prevalent chronic disease (WHO 2020). Importantly, NCDs incur significant human
136 suffering in addition to their estimated economic costs (Kassotis et al. 2020; Attina et al.
137 2016; Trasande et al. 2015; Trasande et al. 2016; Obsekov, Kahn, and Trasande 2022),
138 which further stresses the need for urgent action towards prevention of morbidities
139 associated with NCDs.

140 Chemical exposures are an important contributor to NCDs, especially when they
141 occur during sensitive stages such as early life, or persist over extended periods of time.
142 Several well-studied types of chemicals such as toxic metals, halogenated aromatics,

143 and some pesticides (Bergman et al. 2013; Rojas-Rueda et al. 2021), as well as some
144 members of the endocrine disrupting compounds (Gore et al. 2015; Goralczyk 2021;
145 Demeneix and Slama 2019; Tanner et al. 2020; Chamorro-Garcia et al. 2017) are
146 associated with NCDs such as brain-related disorders, cancers, metabolic disorders,
147 reproductive disorders and cardiovascular disease. Specific FCCs such as BPA and
148 several members of the ortho-phthalates group are associated with NCDs such as heart
149 disease, diabetes, and some forms of cancer (Martínez-Ibarra et al. 2021; Svensson et al.
150 2021) (Table 1). Further, the effects of chemical exposures on risk of NCDs are
151 complex and multifaceted, with some outcomes occurring across generations through
152 transgenerational inheritance (Walker et al. 2018; Feil and Fraga 2012; Chamorro-
153 Garcia et al. 2017). It is also clear that these effects are not limited to laboratory
154 animals, as mixtures of chemicals including FCCs have been associated with adverse
155 health outcomes in prenatally exposed humans (Svensson et al. 2021; Tanner et al.
156 2020; Kortenkamp and Faust 2018; Bornehag et al. 2021; Bornehag et al. 2019;
157 Caporale et al. 2022).

158 [Table 1 near here]

159 NCDs that are increasingly prevalent in the human population and that are
160 associated with hazardous chemical exposures can be grouped into disease clusters. On
161 this basis, we developed the novel concept of Six Clusters of Disease (SCOD) (Fig. 3).
162 The six clusters are cancers, cardiovascular diseases, reproductive disorders, brain-
163 related disorders, immunological disorders, and metabolic diseases. The SCOD concept
164 provides a framework for systematically assessing the safety of chemicals in FCMs,
165 with a focus on the prevention of chemical-associated, highly prevalent, and severe

166 NCDs. As such, the SCOD concept expands current efforts for chemical risk assessment
167 of FCCs.

168 [Figure 3 near here]

169 ***2.2 Current risk assessment of food contact chemicals is not sufficiently***
170 ***protective of human health***

171 The universe of known FCCs comprises at least 14,153 substances, and for at
172 least 1,822 FCCs empirical evidence for migration from food contact articles and
173 materials is publicly available (Geueke et al. 2022). Evidence of human exposure exists
174 for hundreds of these chemicals (Barr et al. 2003; Calafat et al. 2005; Silva et al. 2004;
175 Caporale et al. 2022; Correia-Sá et al. 2017; Cortéjade et al. 2017; Koch and Calafat
176 2009; Pouech et al. 2015; Rudel et al. 2011; Susmann et al. 2019; Isaacs et al. 2022;
177 Domínguez-Romero et al. 2022; Bil et al. 2023; Jung et al. 2022; Ruan et al. 2019). At
178 least 388 FCCs in use today are known to be carcinogenic, mutagenic or toxic to
179 reproduction, possess endocrine disrupting properties, or have other properties of
180 concern such as persistence, and for at least 127 of these FCCs of concern there is
181 evidence for migration from FCMs into food or food simulant (Zimmermann et al.
182 2022).

183 Currently, in the United States (US), Canada, the European Union (EU), China
184 and other countries, chemical risk assessment is required for all migrating substances
185 (Fig. 2). In practice, however, it is predominantly the intentionally used substances that
186 are assessed for their risk to human health (Muncke et al. 2017). Humans are exposed to
187 many more FCCs that are non-intentionally added to the finished food contact material
188 or foodstuff. These NIAS include impurities of the starting substances, reaction by-
189 products, or degradation products of starting substances (like additives) (Horodytska,

190 Cabanes, and Fullana 2020; Qian et al. 2018; Bradley and Coulier 2007; Bauer et al.
191 2019), and also contaminants that accumulate in reused or recycled FCMs (Geueke et
192 al. 2023; Geueke, Groh, and Muncke 2018; Biedermann et al. 2013; Oldring et al.
193 2023). NIAS most often are unidentified, they are common in FCMs with high chemical
194 complexity, and they are likely to be biologically active (Geueke 2018). Under the
195 current chemicals risk assessment paradigm for FCMs, where a chemical's identity
196 must be known, unidentified FCCs cannot be assessed, although, for example, the EU
197 plastic food contact regulation requires the risk assessment of NIAS (EU 2011), and
198 also US FDA's Food Contact Notification has information requirements on impurities
199 and reaction by-products (FDA 2007).

200 A second problem is the lack of testing of substances present in the finished
201 food contact material. Several approaches have been developed to approximate the
202 health risks of unknown NIAS (Koster et al. 2015; Koster et al. 2013; Pieke et al. 2017;
203 Taylor and Sapozhnikova 2022; Leeman and Krul 2015; Omer et al. 2019;
204 Sapozhnikova, Nuñez, and Johnston 2021), but these approaches contain substantial
205 uncertainties related to hazard estimation, chemical identification, and quantification
206 (Bschir accepted; Van Bossuyt et al. 2017) because they are based on assumptions that
207 cannot be entirely supported by empirical evidence. For example, generic thresholds for
208 chronic exposures to nongenotoxic carcinogens were derived from testing chemicals at
209 maximum tolerable doses (MTD) and at 1/2 MTD, but it depends on the exact
210 mechanism by which a chemical exerts its toxicity whether a low-dose extrapolation
211 from MTD dosing is appropriate or not (Bailey et al. 2009; Williams et al. 2009).

212 Finally, because some laws prohibit the use of chemicals that cause cancer in
213 humans or animals, testing methods currently focus on genotoxicity as a proxy for

214 predicting cancer risk (Muncke et al. 2017; Neltner et al. 2013b). But other hazards that
215 are not related to genotoxic effects are currently not systematically assessed, , including
216 outcomes relevant to other chronic NCDs. Thus, there is a need for novel and more
217 robust approaches to more fully evaluate all the relevant hazards to human health
218 associated with FCCs.

219 **3. Our vision: to make safer food contact materials**

220 *3.1 Assessing toxicological effects relevant to the Six Clusters of Disease*

221 Chronic exposure to hazardous chemicals is a known modifiable risk factor for
222 cancer and reducing exposure to hazardous or untested chemicals from consumer
223 products, including FCMs, is a recommended preventive measure (Madia et al. 2019). It
224 is reasonable to assume that the same holds true for other NCDs that are associated with
225 chemical exposures, especially for endocrine disrupting chemicals (Table 1). Indeed,
226 exposure reductions can lower the incidence of disease (Scholz et al. 2022), for example
227 for neurodevelopmental disorders (Bennett et al. 2016), obesity (Mohanto et al. 2021) or
228 male reproductive disorders (Foresta, Tescari, and Di Nisio 2018).

229 NCDs that are increasingly prevalent in the human population and that are
230 associated with hazardous chemical exposures can be grouped into disease clusters. On
231 this basis, we have developed the novel concept of SCOD (Fig. 3). The SCOD concept
232 emerged from discussions with the Food Packaging Forum’s Scientific Advisory Board
233 (SAB) during several meetings between 2016 and 2022. The SCOD concept provides
234 for the first time a framework for systematically assessing the safety of chemicals in
235 FCMs, with a focus on the prevention of chemical-associated, highly prevalent and
236 severe NCDs. As such, the SCOD concept expands current efforts for chemical risk
237 assessment of FCCs beyond cancers induced via a genotoxic mechanism (Beneventi,

238 Tietz, and Merkel 2020; Muncke et al. 2017). For each disease cluster within the
239 SCOD, many widely used FCCs have been associated with relevant diseases in both
240 epidemiology and animal studies (Tables 1 and 2). For some, mechanistic evidence
241 strengthens these associations (Table 2). It is also this mechanistic evidence that
242 provides opportunities to use *in-silico* and *in-vitro* assays to better map toxicity profiles
243 of individual FCCs in finished FCMs, before they are placed on the market, as well as
244 mixtures, extracts and migrates from FCMs and food contact articles. The SCOD
245 provides organizing principles for such an approach.

246 ***3.2 Assessing real-life chemical exposures: testing overall migrate from food*** 247 ***contact materials***

248 All FCCs that are relevant for human exposure should be tested, in other words,
249 FCCs used in the manufacturing of FCMs should be tested as single substances, and the
250 real-life mixture of all migrating FCCs, the *overall migrate*, should also be tested. If the
251 overall migrate displays positive findings in the in-vitro assays, it should be subjected to
252 non-targeted chemical analyses in order to elucidate its chemical composition, including
253 NIAS, and to identify the substances driving the overall migrate's toxicity (Nerín et al.
254 2022). This combined testing and chemical identification approach could inform the
255 development of safer FCMs by selecting less hazardous ingredients and developing
256 manufacturing processes that generate fewer and less biologically active NIAS. Such an
257 approach would be aligned with the proposed Safe and Sustainable by Design
258 framework included in the EU's Chemicals Strategy for Sustainability (EU 2020a).

259 The already available as well as emerging *in-vitro* assays provide an opportunity
260 to identify hazardous properties of single substances and of the overall migrate. *In-vitro*
261 test systems are small-scale, often single-cell or small organism systems, for example

262 human cancer cell lines, bacteria, and fungi (e.g. yeast). Other high-throughput
263 screening assays utilize embryos and larvae from vertebrates such as zebrafish (*Danio*
264 *rerio*) or African clawed frog (*Xenopus laevis*). These assays can be performed
265 efficiently both in terms of time and cost and are usually based on mechanistic
266 pathways (Groh and Muncke 2017; Severin et al. 2017; Akoueson et al. 2023).

267 Test batteries, where several relevant assays are combined simultaneously, can
268 also be operated as high-throughput screening methods such as those developed in
269 Tox21 and ToxCast (Richard et al. 2016; Tice et al. 2013; Filer et al. 2022), which
270 demonstrate the feasibility of this approach. In this way, diverse information about the
271 interaction properties of a single chemical with different biological systems can be
272 generated efficiently, and with lower cost, compared to whole-animal testing used in
273 traditional toxicology. Further, overall migrate, that is, mixtures of chemicals migrating
274 from FCMs, can be tested in such assays, too (Akoueson et al. 2023; Zimmermann et al.
275 2019; Bengtstrom et al. 2016).

276 These assessments should be guided by the SCOD concept. However, gaps exist
277 in the current understanding of molecular pathways related to the SCOD, and these *in-*
278 *vitro* assays remain insufficient to identify the full panoply of potential hazards,
279 especially those mediated by endocrine mechanisms. *In-vitro* assays included in high-
280 throughput test batteries need to be appropriate for predicting relevant human health
281 outcomes; should be demonstrated to be reproducible, sufficiently specific and
282 sensitive; and must be executed transparently (Janesick et al. 2016; Schug et al. 2013).
283 Because of the limited *in-vitro* assays for known pathways and mechanisms of action
284 associated with endocrine disruption and other complex biological cascades, animal
285 testing needs to continue, but actual *in-vivo* tests will be fewer than in the past. For

286 example, no current *in-vitro* approaches would have revealed what is now known to be
287 a feature of some chemical exposures, e.g., transgenerational epigenetic inheritance
288 (Fitz-James and Cavalli 2022). Acknowledging these and other gaps, the European
289 Commission is funding EURION, a program to develop new testing and screening
290 methods (including many *in-vitro* approaches) for identifying endocrine disrupting
291 chemicals (Street et al. 2021).

292 ***3.3 Shifting from the status quo to a more comprehensive approach to testing***

293 Within the SCOD, increasingly available mechanistic information enables an
294 understanding of how chemicals contribute to highly prevalent NCDs. Two emerging
295 frameworks are being implemented to describe how chemicals affect complex diseases
296 and to provide a more uniform approach to evaluating mechanistic evidence: the key
297 characteristics concept, and adverse outcome pathways (AOPs). Both offer
298 opportunities to shift from the status quo, modernize hazard assessments, and develop
299 suitable *in-vitro* assays.

300 ***3.3.1 The Key Characteristics concept: modernizing chemical hazard assessments***

301 The key characteristics concept makes use of information about the properties of
302 hazardous chemicals that have empirical evidence linking them causally to relevant
303 apical (disease) endpoints (Smith et al. 2016). The underlying premise is that chemicals
304 that cause the same disease outcomes in whole organisms share molecular properties
305 (i.e., key characteristics) that are relevant for their hazardous properties. The key
306 characteristics for different disease outcomes are hence defined using empirical
307 evidence for well-characterized chemicals, combined from epidemiological, *in-vivo* and
308 mechanistic studies. These disease-specific key characteristics can then be used to
309 develop mechanistic *in-vitro* assays to screen chemicals for their propensity to

310 contribute to different disease clusters and thereby reduce the need for *in-vivo*
311 experiments while still decreasing scientific uncertainty normally associated with *in-*
312 *vitro* data.

313 The key characteristics were first developed for carcinogens, drawing from
314 existing mechanistic information from thoroughly assessed chemicals that are known to
315 be carcinogenic in humans (Smith et al. 2016; Guyton et al. 2018; Krewski et al. 2019;
316 Al-Zoughool et al. 2019; Guyton and Schubauer-Berigan 2021). Additional key
317 characteristics of other disease-causing chemicals have also been described, such as for
318 hepatotoxicants (Rusyn et al. 2021), endocrine disrupting chemicals (La Merrill et al.
319 2020), female reproductive toxicants (Luderer et al. 2019), male reproductive toxicants
320 (Arzuaga et al. 2019), cardiovascular toxicants (Lind et al. 2021), and immunotoxicants
321 (Germolec et al. 2022). For metabolic toxicants and neurotoxicants, work to describe
322 key characteristics is ongoing. Taken together, the key characteristics approach provides
323 an excellent starting point for the mechanistic understanding of how certain chemicals
324 are associated with NCDs, such as those covered in the SCOD.

325 *3.3.2 Using other mechanistic information to develop suitable in-vitro assays*

326 In addition to the key characteristics, further important mechanistic
327 understanding is becoming available and can be useful to inform development of
328 dedicated *in-vitro* screening assays for hazard assessments of FCCs. Chemicals exert
329 toxic effects by combinations of many different molecular-level events. These
330 mechanistic events leading to apical endpoints of toxicity can be organized in an AOP
331 (Ankley et al. 2010). Several AOPs relevant to NCDs in the SCOD have been proposed,
332 such as estrogen receptor activation leading to breast cancer (Coumoul et al. 2022) and
333 the upregulation of thyroid hormone catabolism (via activation of hepatic nuclear

334 receptors) leading to subsequent adverse neurodevelopmental outcomes in mammals,
335 specifically the loss of cochlear function (Friedman, Crofton, and Gilbert 2022). Thus,
336 AOPs are an emerging approach to organize mechanistic information so that molecular
337 or cellular-level targets can be identified for developing *in-vitro* assays that are relevant
338 to the SCOD.

339 3.3.3 *The novel approach: A vision for safer food contact materials*

340 Based on the presumption that mechanistic *in-vitro* testing of chemicals supports
341 the prevention of NCDs within the SCOD, we propose a novel approach for testing
342 FCCs that

- 343 (1) covers individual FCCs as well as real-life mixtures, migrating (or extractable)
344 from finished FCMs, including all known and unknown NIAS,
- 345 (2) assesses the health impacts of FCCs and real-life mixtures with respect to the
346 most prevalent NCDs in the human population, and
- 347 (3) evaluates effects that are upstream from the disease, relying on mechanistic
348 information and *in-vitro* screening approaches (wherever possible) to accurately
349 predict health effects induced by FCCs and migrates.

350 This shift from current practice to the proposed approach is summarized in Fig. 4,
351 and a detailed overview is provided in Fig. 5. Our approach overcomes the most
352 challenging shortcomings of the current testing paradigm of chemical hazard
353 assessment of FCMs, fully recognizing that to assess all adverse effects of chemicals on
354 biological systems, adequate *in-vivo* testing is required, where additional aspects would
355 be addressed such as metabolic activation, unknown modes of action leading to apical
356 endpoints, and transgenerational effects. However, we also realize that such extensive,

357 multigeneration *in-vivo* testing may not always be feasible for various reasons,
358 including ethical and practical ones. Therefore, we propose this vision to improve FCC
359 testing from the currently too limited scope towards a much more comprehensive yet
360 feasible approach that holds promise for better protection of public health.

361 [Figure 4 near here]

362 [Figure 5 near here]

363 **4. Implementing the vision: assessing impacts of FCCs and relevant mixtures** 364 **on human health outcomes in the SCOD using mechanistic approaches**

365 Here we review the mechanistic basis for each of the disease clusters included in
366 the SCOD, and selectively highlight available *in-vitro* testing methods. Importantly,
367 some available assays cover key characteristics that are relevant for several disease
368 clusters.

369 This vision for expanded hazard assessment of FCMs is based on the finding
370 that for each of the disease clusters included in the SCOD, some mechanistic
371 understanding is available for the way that chemicals cause disease (Table 2).

372 [Table 2 near here]

373 **4.1 Cancer**

374 As defined by Willis,

375 A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is
376 uncoordinated with that of the normal tissues and persists in the same excessive
377 manner after cessation of the stimulus which evoked the change (Willis 1948).

378 Regarding cancer causation, the somatic mutation theory posits that cancer is a

379 cellular disease caused by mutations of genes that disrupt the control of cell
380 proliferation. Yet, substantive contradictions exist between this theory and empirical
381 evidence (Naxerova 2021), which inspired competing theories consider cancer as a
382 problem of tissue organization akin to organogenesis (Sonnenschein and Soto 2020;
383 Maffini et al. 2004; Rønnov-Jessen and Bissell 2009). Importantly, not all carcinogens
384 are mutagens (Keri et al. 2007) and, thus, carcinogenicity cannot be equated with
385 genotoxicity. Yet, because legal requirements restrict the use of cancer-causing agents
386 in FCMs, testing of FCCs has focused on genotoxicity as a proxy to identify
387 carcinogenic substances.

388 Both carcinogens and mutagens are found in FCMs including 1) formaldehyde,
389 a known human carcinogen (IARC Group 1) (IARC 2012a), which migrates from
390 various plastics including melamine-formaldehyde plastics used as tableware for
391 children, and polyethylene terephthalate plastic (PET) (Kim et al. 2021; Bach et al.
392 2013); 2) antimony trioxide, which “is reasonably anticipated to be a human
393 carcinogen” (NTP 2021) and “probably carcinogenic to humans” (IARC Group 2A)
394 (IARC 2022), and it is used in the manufacture of PET, where antimony is found to
395 migrate into soft drinks (Westerhoff et al. 2008; Bach et al. 2013); and 3) per- and
396 polyfluoroalkyl substances (PFAS) are widely used in the manufacture of FCMs as
397 processing aids in plastic and paper food contact material production (Trier, Granby,
398 and Christensen 2011; Minet et al. 2022), and perfluorooctanoic acid has limited
399 evidence for testicular and kidney cancers in humans and is “possibly carcinogenic to
400 humans” (IARC Group 2B) (Benbrahim-Tallaa et al. 2014).

401 The key characteristics for carcinogens reveal that these chemicals can be
402 mutagens, but that there are numerous other common features for these agents as well,

403 such as inducing oxidative stress, modulating receptor-mediated effects and inducing
404 chronic inflammation (Smith et al. 2016; Guyton et al. 2018; Krewski et al. 2019; Al-
405 Zoughool et al. 2019; Guyton and Schubauer-Berigan 2021). Guyton and Schubauer-
406 Berigan (2021) recommended the use of *in-vitro* assays based on the key characteristics
407 to identify carcinogens in high-throughput screening (Guyton and Schubauer-Berigan
408 2021). Further, Rider et al. (2021) proposed methods to use the key characteristics to
409 test chemical mixtures and their propensity to affect cancer development including in
410 mixtures of chemicals with different key characteristics of carcinogens (Rider et al.
411 2021). Approaches such as these will provide important information for testing mixtures
412 such as the overall migrate from finished FCMs. Methods for evaluating genotoxicity
413 are readily available, validated, and trusted. Chemicals are considered genotoxic if they
414 damage the structure, information content, or segregation of DNA, with mutagenicity
415 (i.e. changes to the nucleotide sequence) being a sub-type of genotoxicity (OECD
416 2015).

417 These methods include (Muncke 2009):

- 418 • **Mutagenicity:** The Ames test, based on bacterial reverse mutagenicity, is the
419 most employed test for mutagenicity (Organisation for Economic Co-operation
420 and Development (OECD) test guideline (TG) 471). A mammalian cell (mouse
421 lymphoma) gene mutation test (OECD TG 490) is also available (OECD 2022)
- 422 • **Chromosomal aberration:** Cultured mammalian cells are assessed for the
423 presence of chromatid-type and chromosome-type aberrations during metaphase
424 (OECD TG 473)
- 425 • **Micronucleus:** Micronuclei represent chromosomal damage (chromosome
426 fragments or whole chromosomes) that have been transmitted to daughter cells.

427 Micronuclei can be assessed *in-vitro* by using mammalian cells (OECD TG 487)
428 or *in-vivo* with erythrocytes collected from bone marrow or peripheral blood
429 (OECD TG 874)

430 These methods are recommended or required for assessing intentionally used
431 FCCs (EFSA 2008; FDA 2007). Several other *in-vitro* assays for assessing the
432 genotoxic potential of FCCs are also available (Pinter et al. 2020). However, these
433 strategies have not kept pace with discoveries in cancer biology (Chiara, Indraccolo,
434 and Trevisan 2020). Currently, no *in-vitro* assays are available that capture features of
435 carcinogenicity beyond genotoxicity, but research is underway to address this technical
436 gap (Hwang et al. 2020). On the other hand, the causal role of the microenvironment in
437 carcinogenicity, as put forward by tissue-based theories on carcinogenicity (Maffini et
438 al. 2004), is not captured by such *in-vitro* assays, because the reciprocal interactions
439 between stroma and parenchyma during development, regeneration, and remodeling are
440 not being considered (Soto et al. 2013). Although *in-vivo* assays involving mammals are
441 available, traditional 2-year rodent carcinogenicity studies (OECD TG 451), either
442 alone or in combination with chronic toxicity studies, are rarely performed for FCCs.

443 **4.2 Cardiovascular diseases**

444 Cardiovascular diseases (CVDs) are a group of disorders arising due to
445 dysfunction of the heart and blood vessels. The most recognized forms of CVD,
446 coronary heart disease and cerebrovascular disease, result in damage to tissues caused
447 by limited or complete loss of blood supply (WHO 2021).

448 FCCs including several phthalates and bisphenols contribute to the causation of
449 CVDs, independent of obesity and diabetes (Lind et al. 2021). Bisphenols can disrupt
450 calcium signalling in myocardium and vasculature; and phthalates and bisphenols are

451 oxidant stressors that accelerate coronary and other arterial inflammation (Lind et al.
452 2021). In the US alone, 100,000 premature deaths from CVD among 55–64-year-olds
453 each year are attributed to exposure to one phthalate, DEHP (Wen, Wang, and Zhang
454 2022). Other FCCs, such as antimony, may also impair cardiovascular function and
455 accelerate CVDs (El-Kersh et al. 2022).

456 Lind et al. (2021) compiled the key characteristics of cardiovascular toxicants
457 and provided a comprehensive overview of robust and sensitive *in-vitro*, *ex vivo* and *in-*
458 *vivo* assays that are available for measuring dysregulation of Ca²⁺ ion homeostasis and
459 resulting arrhythmogenic activities of chemicals. For example, the increased risk for
460 CVDs associated with higher exposures to BPA is mechanistically associated with Ca²⁺
461 release and reuptake resulting in proarrhythmic delays after depolarizations in isolated
462 cardiomyocytes. BPA promotes Ca²⁺-mediated arrhythmias *ex vivo* in the whole heart
463 of rats and mice (Yan et al. 2011). However, this is only one of many possible
464 mechanisms for inducing CVDs, and further assay development is required.

465 Although several FCCs have been associated with CVDs, cardiovascular
466 toxicity is generally not evaluated for FCCs, whether they are intentionally used to
467 make FCMs or NIAS present in finished FCMs. This is in part due to a reliance on *in-*
468 *vivo* guideline testing of general toxicity for chemicals migrating at very high levels and
469 limited to assessment of neoplastic and non-neoplastic cardiac lesions in rodent models,
470 which can be confounded by a high incidence of background pathology in many of the
471 rodent strains used for toxicity testing (Gear, Kendzioriski, and Belcher 2017). However,
472 these are insensitive apical endpoints that only identify highly cardiotoxic chemicals
473 that result in robust pathology but miss subtle molecular effects (Gao and Wang 2014;
474 Jokinen et al. 2011).

475 We recommend that comprehensive testing for all new chemicals include *in-*
476 *vitro* and *in-silico* testing harmonized with the Comprehensive *in-vitro* Proarrhythmia
477 Assay approach (CiPA) (FDA 2022; CIPA 2019). The CiPA initiative was launched to
478 address limitations in the current cardiac safety testing methods used to assess the risk
479 for adverse cardiac events of new drugs. The CiPA aims to develop a new approach for
480 evaluating the potential of drugs to cause cardiac arrhythmias, particularly a specific
481 type known as Torsades de Pointes (TdP). It is a multi-step approach that combines *in-*
482 *vitro* assays and computational modeling to assess proarrhythmic risk and predict the
483 risk of TdP by considering the complex interactions of multiple ion channels and
484 cellular components involved in cardiac electrophysiology. The CiPA could be used as
485 an important approach for identifying cardiotoxic hazards of FCCs.

486 **4.3 Brain-based disorders**

487 Disrupted neurodevelopment can have numerous consequences including a
488 lower intelligence quotient, delayed language acquisition, attention deficit hyperactivity
489 disorder (ADHD), and autism (Caporale et al. 2022; Bornehag et al. 2021; Kim et al.
490 2022). Because the role of thyroid hormone in brain development is well established,
491 hypothyroidism, especially during early development, is also a condition of concern
492 upstream of neurodevelopmental disorders. Neurotoxicity can also result from impaired
493 neuronal function due to a variety of factors, such as neuronal misplacement during
494 development, altered synapses, hypomyelin, or degeneration. Other neurodegenerative
495 conditions that typically arise later in life include Parkinson's disease, Alzheimer's
496 disease, and other forms of dementia.

497 The role of FCCs in the causation of many brain-based disorders is well
498 established, with substantial contribution to the burden of disease for both

499 neurodevelopmental and neurodegenerative disorders (Attina et al. 2016). For example,
500 FCCs that interfere with thyroid hormone systems or sex steroids (e.g., phthalates and
501 perchlorate) can affect brain development as well as cognitive function in adults
502 (Bennett et al. 2016; Grandjean and Landrigan 2006). The vulnerability of the
503 developing brain and the lack of systematic assessment of neurodevelopmental toxicity
504 for FCCs raises serious concerns (Maffini, Trasande, and Neltner 2016; Mustieles and
505 Fernández 2020). At present, the key characteristics of neurotoxicants remain
506 undescribed, but relevant work is ongoing.

507 In addition to assays covering interference with the thyroid and sex steroid axes,
508 *in-vitro* testing of neurotoxicants requires sophisticated and reliable models due to the
509 complexity of the brain (Marty et al. 2021). Neuronal cell lines, primary central nervous
510 system cells, transformed neuronal precursors and stem cell derived progenitor cells are
511 used in neurotoxicity assays (Arshajyothirmayi and Gulia 2022) to evaluate endpoints
512 including migration, synapsis formation, network activity and differentiation. Although
513 single-cell cultures are informative, multi-cell type and three-dimensional models
514 utilizing microfluidics more adequately represent the diversity and spatial properties of
515 the brain (Caffrey, Button, and Robert 2021; Kilic et al. 2016; Maoz 2021; Park et al.
516 2021), but high throughput versions of these methods are not yet available, and thus
517 their use in evaluating FCCs has been limited. Additional *in-vitro* assays for chemical
518 screening of neurotoxicants are under development in EU-funded research programs
519 (Cediel-Ulloa et al. 2022) and research is ongoing to develop further *in-vitro* assays
520 targeting the thyroid system (Kortenkamp et al. 2020). Recently, the establishment of a
521 human cell-based *in-vitro* battery has been reported; it combines 10 assays selected to
522 cover major key events in the relevant AOPs (Sachana et al. 2021) and was shown to
523 provide 82% sensitivity in that it was able to identify 24 out of 28 known neurotoxicants

524 (Blum et al. 2022).

525 New low- and medium-throughput screening assays have been developed. For
526 example, the nematode is a promising model for evaluating known neurodevelopmental
527 toxicants and could be expanded to profiling chemicals with unknown neurotoxicity
528 (Ruszkiewicz et al. 2018; Hunt et al. 2018). Spontaneous movements (Parng et al.
529 2007), number and location of neurons (Rericha et al. 2022), and behavioral effects
530 (Fitzgerald et al. 2021) are some of the neurological endpoints measured in zebrafish.
531 Validated high-throughput screening assays using African clawed frog tadpoles are also
532 available (OECD TG 248).

533 *In-vivo* testing in rodents can be used to assess different functional aspects of
534 neurotoxicity including impacts on cognition, learning and memory; and anxiety-like,
535 depressive-like and reproductive behaviors. OECD developmental neurotoxicity
536 (OECD TG 426) and extended one-generation reproductive toxicity assays (OECD TG
537 443) include optional measurements of learning and memory, motor and sensory
538 function, motor activity, and auditory startle. Neurodegeneration is not covered because
539 this endpoint can only be studied in animals which age, and animals used in assays are
540 typically not kept until the end of their natural lifetime where neurodegeneration would
541 manifest itself (Huff, Jacobson, and Davis 2008).

542 ***4.4 Obesity and Metabolic diseases***

543 Metabolic diseases, including obesity, involve the many tissues that comprise
544 the metabolic system (Mohajer et al. 2021). These include adipose tissue, skeletal
545 muscle, pancreas, liver, gastrointestinal tract, bone, and brain. Type-2 diabetes, an
546 important metabolic disease with increasing prevalence in human populations, occurs
547 due to systemic insulin resistance, often with an increasing production of insulin by the

548 pancreas. Type-1 diabetes occurs due to a progressive loss of β -cell insulin secretion.
549 Non-alcoholic fatty liver disease is another metabolic disease with increasing
550 prevalence in human populations.

551 While poor diet and insufficient physical activity are considered the chief drivers
552 of the obesity and diabetes twin pandemics, chemical exposures (for example, to
553 phthalates, bisphenols, parabens, PFAS, etc.) can disrupt the balance between energy
554 expenditure and energy intake (Heindel et al. 2022). A large comprehensive review of
555 metabolic disrupting chemicals, including those that can induce obesity (obesogens),
556 provides strong evidence that numerous FCCs are associated with type-2 diabetes,
557 obesity, and fatty liver disease (Heindel 2019). The key characteristics of metabolic
558 disruptors and obesogens are being compiled. Rusyn et al. (2021) have described the
559 key characteristics of acute and chronic human hepatotoxicants and note that only one
560 of 12 key characteristics are specific to liver tissue (KC9: causing cholestasis) (Rusyn et
561 al. 2021), indicating that there are overlaps with the key characteristics of other
562 toxicants, i.e. carcinogens, cardiovascular toxicants, endocrine disrupting chemicals,
563 and male and female reproductive toxicants.

564 The simplest assays to identify an obesity hazard are those that measure the
565 effect of chemical exposures on the development of adipocytes (Kassotis et al. 2022;
566 Kassotis and Stapleton 2019; Seo, Shin, and Kim 2019). Primary preadipocyte cultures,
567 or mesenchymal stem cell assays, use animal or human cells to assess proliferation and
568 differentiation into adipocytes (Desai et al. 2018b; Shoucri et al. 2018; Kassotis and
569 Stapleton 2019; Chamorro-Garcia and Blumberg 2019; Lane et al. 2014; Tang, Otto,
570 and Lane 2004; Pillai et al. 2014). Using this *in-vitro* assay, a recent study found that
571 around one third of tested plastic food contact articles contained metabolic disrupting

572 chemicals (Völker et al. 2022). Recently, spheroid adipocyte models have been
573 developed that improve the efficiency and speed of differentiation (Turner et al. 2017)
574 and can be used for a more comprehensive understanding of adipocyte physiology than
575 monolayer cultures. The zebrafish obesogenic test offers an *in-vivo* approach to
576 screening chemicals that target adiposity; it measures adipocyte lipid droplet size and
577 normalized triacylglycerol content as an assessment of adiposity in a whole-organism
578 assay of larvae to test for obesogenic and anti-obesogenic chemicals and mixtures
579 (Tingaud-Sequeira, Ouadah, and Babin 2011).

580 Other non-adipocyte cell lines, when well characterized such as the mouse bone
581 marrow-derived mesenchymal stem cells (mBMSCs), are also useful for mechanistic
582 studies (Auerbach et al. 2016; Janesick et al. 2016). In addition to adipocyte
583 differentiation, several other mechanisms are implicated with metabolic disease
584 causations, for example the disruption of energy homeostasis at the level of the
585 hypothalamus and brain. Therefore, *in-vitro* assays that examine effects on
586 hypothalamic neurons are useful (Ye et al. 2016; Loganathan et al. 2018).

587 No assays have been developed to identify metabolic disruptors acting as
588 diabetogens. Ongoing projects are developing assays to measure β -cell function and
589 survival (Audouze et al. 2020; Legler et al. 2020; Küblbeck et al. 2020) using rodent β -
590 cell lines (INS-1E and MIN-6) and a human β -cell line (ENDOC- β H1). Assays of
591 insulin function on the human liver cell line HepaRG, the skeletal muscle cell line
592 C2C12, and adipocytes are also under investigation (Legler et al. 2020). One well
593 established system of assays employing both *in-vitro* and *in-vivo* methods has been used
594 to explore the relationship between BPA and type-2 diabetes (Dos Santos et al. 2022).

595 The most used assays to screen chemicals for effects on the liver use the

596 HepaRG and HepG2 cell lines. The HepG2 cell line can be customized with different
597 expression levels of various drug metabolizing enzymes (Tolosa et al. 2018). Other 2D
598 and 3D *in-vitro* approaches use primary hepatocytes, immortalized liver cell lines, and
599 hepatocytes derived from stem cells that are grown in monolayers, as spheroids or
600 organoids, or used in emerging technologies (like organ-on-a-chip) to identify liver
601 toxicants (Yang et al. 2023). Each of the approaches available has strengths and
602 weaknesses; for example, the use of human primary hepatocytes in 2D culture can
603 produce patient-specific evaluations that account for differences in metabolism and
604 sensitivity, but these assessments come at high cost. Several of these methods are
605 currently being used to evaluate liver toxicity in the screening of pharmaceuticals
606 (Serras et al. 2021), making them similarly well suited to evaluate FCCs for potential
607 effects on liver outcomes.

608 ***4.5 Immunological disorders***

609 The immune system is an intricate network of many different, highly specialized
610 cells interacting with each other and with the nervous and endocrine systems (Nicholson
611 2016). Disorders of the immune system include autoimmune disorders such as multiple
612 sclerosis, Graves' and Hashimoto's diseases, lupus, Celiac's, Addison's, and
613 rheumatoid arthritis, among others. Other diseases including type-1 diabetes and asthma
614 have an important immune component. Therefore, assays for immunotoxicity need to
615 capture a multitude of potential effects, including immunosuppression,
616 immunostimulation, hypersensitivity reactions, mechanisms of autoimmunity, and
617 developmental immunotoxicity, e.g., delayed immunotoxic responses to toxic
618 influences (Germolec et al. 2017).

619 The human immune system is highly effective, but also sensitive to synthetic

620 chemical insults during development and adult life. Effects of chemicals on the immune
621 system are less well understood in humans than other disease endpoints, but emerging
622 evidence implicates PFAS exposure in reducing immune response to vaccines and
623 increasing susceptibility to infections in early life (Grandjean et al. 2017). Other FCCs
624 including bisphenols and phthalates increase the risk of atopy and asthma (Xie et al.
625 2016; Wang, Chen, and Bornehag 2016; Kim et al. 2017), and infections in early life
626 (Gascon et al. 2015).

627 The key characteristics of immunotoxicants have been described (Germolec et
628 al. 2022). This offers a starting point for development of suitable *in-vitro* assays for
629 testing FCCs for immunotoxicity. Due to the complexity of the immune system
630 components and responses, a comprehensive battery of *in-vitro* assays covering all
631 relevant aspects of immunotoxicity has not been established. However, several *in-vitro*
632 assays, dealing for example with direct immunosuppression, allergic hypersensitivity, or
633 autoimmunity, are being developed to detect a range of immunotoxicants (Corsini and
634 Roggen 2017; Luebke 2012; Deprouw et al. 2022; Naidenko et al. 2021) and these
635 assays could be used to screen FCCs (Ogungbesan, Neal-Kluever, and Rice 2019).

636 **4.6 Reproductive disorders**

637 In industrialized countries, male reproductive health has declined over the past
638 decades, including a 50-60% decrease in sperm counts since 1973 (Levine et al. 2017;
639 Skakkebak et al. 2022; Levine et al. 2022) and an increase in testicular cancer (Znaor et
640 al. 2022). Female fertility is also affected, as are maternal health and pregnancy
641 outcomes, and conditions such as polycystic ovary syndrome (PCOS), endometriosis,
642 and premature ovarian failure (Boomsma et al. 2006).

643 The sperm count decrease is associated with chemical exposures (to, e.g.
644 phthalates), especially during fetal development (Skakkebaek, Rajpert-De Meyts, and
645 Main 2001). Strong evidence from animal experiments support this interpretation (Gore
646 et al. 2015; Skakkebaek et al. 2016; Jorgensen et al. 2021; Kortenkamp 2020). FCC
647 exposures are also associated with PCOS (Soave et al. 2020), and other aspects of
648 reproductive toxicity (Nerín et al. 2020; Garcia-Calvo et al. 2020a). These adverse
649 outcomes have even been found for FCCs promoted as safer alternatives to hazardous
650 chemicals such as the plasticizer 1,2-cyclohexane dicarboxylic acid diisononyl ester
651 (tradename Hexamoll DINCH) (Boisvert et al. 2016), which is used as a replacement
652 for DEHP and other phthalates. Several FCCs such as BPA have been studied for
653 mechanistic-level impacts on female fertility, including oogenesis, folliculogenesis, and
654 altered expression of gonadotropin and gonadotropin hormone-releasing hormone
655 receptors (Vessa et al. 2022a). The key characteristics of male (Arzuaga et al. 2019) and
656 female reproductive toxicants (Luderer et al. 2019) have been described. Development
657 and function of the reproductive system is fundamentally dependent on sex hormone
658 action. Thus, the key characteristics of endocrine disrupting chemicals (La Merrill et al.
659 2020) are also relevant to the study of chemicals that affect reproductive outcomes.
660 However, a systematic overview of available *in-vitro* assays for hazard identification of
661 endocrine disrupting chemicals that affect male and female fertility is unavailable.

662 *In-vitro* assays that identify chemical interference with sex hormone production
663 and signalling have been validated (OECD TG 493, 455, 458, 456). These include
664 assays based on nuclear receptor activation and steroid hormone synthesis. The bovine
665 oocyte maturation assay (ECVAM TM 2010-05) is also a reproduction-relevant *in-vitro*
666 assay. A good correlation between *in-vitro* results and *in-vivo* observations has been
667 established for female fertility endpoints (Corton et al. 2022; Pinto et al. 2018).

668 Validated *in-vivo* assays exist to evaluate reproductive toxicity for impacts on both male
669 and female fertility (OECD TG 443), but these may not be sufficiently sensitive or
670 comprehensive, as they fail to evaluate numerous key characteristics of male and female
671 reproductive toxicants (Luderer et al. 2019; Arzuaga et al. 2019).

672 **5. What is needed to implement the vision for safer food contact materials?**

673 To achieve our vision, we propose a multi-pronged approach that is grounded in
674 the SCOD concept, which includes many of the most prevalent NCDs of high relevance
675 to human health. We identified three components needed to realize this vision:
676 analytical methods and testing strategies, data integration and interpretation, and science
677 to inform decision making.

678 ***5.1 Analytical methods and testing strategies***

679 In Section 4 we list several available and emerging assays used in the
680 identification of hazard for each of the SCOD. However much more is needed,
681 especially high-throughput non-animal and low-medium throughput assays with non-
682 mammalian models that are specific, sensitive, reliable and robust, and adequate for
683 predicting effects relevant to humans. These assays would overcome challenges with
684 cost, time, and scientific relevance as the selection of suitable *in-vitro* assays would be
685 based on robust mechanistic evidence from key characteristics and AOPs. Identification
686 of the key characteristics for brain disorders and metabolic diseases will form the basis
687 for identification and/or development of relevant *in-vitro* assays to identify hazardous
688 chemicals related to these clusters. For *in-vitro* testing based on mechanistic pathways
689 to succeed, additional dedicated expertise and financial support are needed to identify
690 assays that would address relevant key characteristics. This work is ongoing and the
691 website keycharacteristics.org collates all available information and publications in this

692 area (Key Characteristics 2022). It also remains to be shown if *in-vitro* assays based on
693 the key characteristics of hazardous chemicals will be sufficiently predictive of
694 chemical hazards when used in pre-market assessments, rather than in ex-ante
695 evaluations (where the key characteristics are currently used).

696 Another important aspect of testing is the development and validation of
697 methods that reflect real-world chemical exposures from FCMs, including the effects of
698 metabolites formed from FCCs in the human body. Migration testing protocols exist but
699 ongoing research efforts need to be expanded and validated to ensure minimal loss of
700 potentially hazardous chemicals during sample preparation (e.g. by using polar and
701 apolar food simulants and by capturing not only non-volatile compounds, but also those
702 that are semi-volatile and volatile) (Nerín et al. 2022; Oldring et al. 2023).

703 Lastly, a battery of screening assays addressing the SCOD needs to be defined
704 and validated. This step will need the contribution of experts in each field to ensure that
705 the selected endpoints are reliable and result in high confidence.

706 Implementation of this vision will depend on the successful progress in all of
707 these areas.

708 ***5.2 Data interpretation and integration***

709 Methods must be developed to interpret and corroborate *in-vitro* test results.
710 Individual assays should be integrated into an overall high-level / aggregated scheme
711 (e.g. using visualization approaches such as ToxPi (Rajkumar et al. 2022; Marvel et al.
712 2018)). Also, non-targeted chemical analyses are challenging, as confirmation of
713 identified compounds is very time- and labour intensive, and at times not possible at all.
714 Also, reliable quantification of chemicals that lack analytical standards is not possible.
715 Therefore, non-targeted approaches need to be advanced to allow for better

716 identification of currently unknown compounds, especially when present at low
717 concentrations. One way to improve the latter is to create comprehensive and open mass
718 spectrometry libraries of FCCs, including NIAS. Ideally, an open-access repository of
719 information about food contact material manufacturing processes and the major FCCs
720 associated with specific materials should be generated. Confidential business
721 information poses a critical obstacle, as the full disclosure of the chemical composition
722 of FCMs is commonly not available. Accordingly, a mechanism needs to be developed
723 that enables such an FCC library without infringing on intellectual property rights.

724 ***5.3 Science for decision making***

725 The results of testing single chemicals or overall migrate (or, for a worst-case
726 assessment, the extract) from a finished FCM (i.e., an FCA) using a battery of assays for
727 each of the SCOD would need to be interpreted and integrated with available evidence
728 to reach a conclusion within a regulatory context. A framework, similar to that available
729 for read-across (Lizarraga et al. 2023; European Chemicals Agency 2017), should be
730 developed to effectively utilize results and support conclusions that are actionable for
731 policy makers and regulatory enforcement. The experience gained from development of
732 effect-based trigger values for water quality assessment in Europe could be highly
733 informative (Escher et al. 2018; Neale et al. 2023). Here, effect-based trigger values
734 have been developed as a means to interpret the results of *in-vitro* assays through
735 linking the existing water quality guideline values to observed levels of bioactivity
736 elicited by a reference chemical. Then, if a test chemical or mixture causes an activity
737 above the trigger value set for a specific assay, it is highlighted for a follow-up
738 assessment, such as calculation of concentration factors and *in-vitro* to *in-vivo*
739 extrapolation (Escher and Neale 2021; Robitaille et al. 2022; Escher, Neale, and Leusch
740 2015). In theory, effect-based trigger values for FCMs could be developed following the

741 same principle, e.g. by matching effect concentrations in relevant bioassays with
742 existing specific migration limits for FCCs of concern, and possibly factoring in
743 additional exposure-related parameters. This approach appears highly promising, since
744 it has been demonstrated that derivation of effect-based trigger values greatly facilitates
745 regulatory and practical uptake of *in-vitro* methods into specific assessment pipelines
746 (Neale et al. 2023), but it is evident that further dedicated efforts are required for an
747 effective implementation of such an approach to the safety assessment of FCMs.

748 **6. Conclusion**

749 The novel approach we present here is in line with the goals laid out in the EU's
750 Chemicals Strategy for Sustainability (EU 2020a), the EU Farm to Fork Strategy (EU
751 2020b), and the European Parliament's report on FCMs (European Parliament 2016),
752 which emphasize the need for revising the food contact material regulation in Europe to
753 adequately reflect recent scientific understanding and improve compliance. Further, this
754 work adds to previous publications on policies and methods related to the risk
755 assessment of food contact chemicals and materials (Zimmermann et al. 2022; Muncke
756 et al. 2020; Muncke et al. 2017), and to the use of new approach methodologies for
757 assessing the health impacts of industrial chemicals (Stucki et al. 2022).

758 We think that our vision to create safer FCMs by linking hazard identification
759 more directly to human health has the potential to spur innovation in assay development
760 and testing, and ultimately, for safer materials as such. Additionally, new findings on
761 the key characteristics for the NCDs included in the SCOD, as well as mechanistic
762 understanding derived from AOP research, will support the development of new assays.

763 Awareness of adverse health effects of synthetic chemicals is increasing globally,
764 and the need is obvious for significant and urgent improvements in the ways that risks

765 are assessed and managed for FCCs (Fenner and Scheringer 2021).

766 **Acknowledgements**

767 We are grateful to Michele La Merrill for constructive comments on this manuscript.

768 **Declarations**

769 *Competing Interests*

770 The authors have no competing interests to declare. For the sake of transparency, the
771 authors list their relationships with various research funders and other organizations in
772 the following. As researchers employed by the Food Packaging Forum Foundation
773 (FPF) (JMB, BG, JM, LZ) or working pro bono as members of the Foundation's board
774 (TB, JPM, MS) and its Scientific Advisory Board (SAB) (AMA, TJC, KJG, JJH, MVM,
775 OVM, AN, CN, AMS, LT, MW, RTZ), we report that the FPF receives unconditional
776 donations from diverse companies that may be affected by the research reported in this
777 manuscript. FPF funders have no influence on any of the work at FPF and were not
778 involved in any way in the preparation of this manuscript. TB declares that he serves as
779 the board member of the International Panel on Chemical Pollution (IPCP), the Swedish
780 Toxicological Council and the EU Commission's Committee on Health, Environmental
781 and Emerging Risks (SCHEER). All those activities are pro bono and have no bearing
782 on the content of the manuscript. None of the aforementioned organizations have had
783 any impact on the content of the manuscript. TJC declares that he is the creator-founder
784 of Sudoc, LLC, which deploys TAML catalysts for many applications and has potential
785 for remediating FCCs in water. JL reports that she receives funding for another research
786 project (ZonMw/Health-Holland Microplastics and Health project MOMENTUM
787 458001101) of which some partners may be affected by the research reported here.

788 MVM is a paid consultant to the FPF. OVM is one of the representatives of the
789 European Parliament on the European Chemical Agency's Management Board. JPM is
790 co-founder and board member of Sudoc and he declares to have given all his shares to
791 an irrevocable grantor trust so that he will not benefit financially if the company is
792 successful. AN declares to have received travel reimbursement from universities, NGOs
793 and scientific societies, to speak about endocrine-disrupting chemicals. LNV has
794 received travel reimbursements from universities, governments, NGOs, and industry.
795 She has received research funding from the US National Institutes of Health, the
796 University of Massachusetts Amherst, and NGOs including the Cornell Douglas
797 Foundation, the Allen Family Foundation, and the Great Neck Breast Cancer Coalition.
798 She is a scientific advisor to Sudoc LLC. The FPF foundation board, whose members
799 have no connection with any of the FPF's funders and receive no remuneration for their
800 work, is legally obliged to guarantee that the work of the FPF is in no way influenced
801 by the interests or views of the funders.

802 *Authors' contributions*

803 This manuscript was initiated by the FPF's SAB and guests participating in SAB
804 meetings in 2017, 2018, 2019, 2020, 2021; AMA, MVM, JM, JPM, RTZ and MS were
805 responsible for preparing an outline and a first version; JM, LVM, MVM and MS edited
806 the final draft, and all authors contributed to the various intermediate versions, wrote
807 separate sections of the manuscript, and approved the final version.

808 *Funding*

809 This work was supported by the FPF's own resources. FPF is a charitable foundation
810 and it funded four meetings of its SAB with external scientific experts as guests (SMB,
811 BCA, FAvH, JL, LNV) during which this manuscript was prepared. Funding for travel

812 and accommodation was provided for three meetings and two additional meetings were
813 held online. Neither FPF's SAB members nor guest participants were reimbursed for
814 their contributions to this manuscript. FPF's funding sources are declared on its website
815 (<https://www.foodpackagingforum.org/about-us/funding>). MS acknowledges funding by
816 the CETOCOEN PLUS project (CZ.02.1.01/0.0/0.0/15_003/0000469), the project
817 CETOCOEN EXCELLENCE (CZ.02.1.01/0.0/0.0/17_043/0009632), and RECETOX
818 RI (LM2018121) financed by the Czech Ministry of Education, Youth and Sports.

819 *Availability of data and materials*

820 Not applicable.

821 **References**

- 822 Akash, Muhammad Sajid Hamid, Shakila Sabir, and Kanwal Rehman. 2020. 'Bisphenol
823 A-induced metabolic disorders: From exposure to mechanism of action',
824 *Environmental Toxicology and Pharmacology*, 77: 103373.
- 825 Akoueson, F., I. Paul-Pont, K. Tallec, A. Huvet, P. Doyen, A. Dehaut, and G. Duflos.
826 2023. 'Additives in polypropylene and polylactic acid food packaging: Chemical
827 analysis and bioassays provide complementary tools for risk assessment',
828 *Science of The Total Environment*, 857: 159318.
- 829 Al-Zoughool, Mustafa, Michael Bird, Jerry Rice, Robert A. Baan, Méliissa Billard,
830 Nicholas Birkett, Daniel Krewski, and Jan M. Zielinski. 2019. 'Development of
831 a database on key characteristics of human carcinogens', *Journal of Toxicology
832 and Environmental Health, Part B*, 22: 264-87.
- 833 Alger, Heather M., Maricel V. Maffini, Neesha R. Kulkarni, Erin D. Bongard, and
834 Thomas Neltner. 2013. 'Perspectives on How FDA Assesses Exposure to Food
835 Additives When Evaluating Their Safety: Workshop Proceedings',
836 *COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY*, 12:
837 90-119.
- 838 Ankley, G. T., R. S. Bennett, R. J. Erickson, D. J. Hoff, M. W. Hornung, R. D. Johnson,
839 D. R. Mount, J. W. Nichols, C. L. Russom, P. K. Schmieder, J. A. Serrano, J. E.
840 Tietge, and D. L. Villeneuve. 2010. 'Adverse Outcome Pathways: A Conceptual

841 Framework To Support Ecotoxicology Research And Risk Assessment. ',
842 *Environmental Toxicology and Chemistry*, 29: 730-41.

843 Arshajyothirmayi, V. A., and Kamalesh K. Gulia. 2022. '26 - Neurotoxicity assays.' in
844 P. V. Mohanan (ed.), *Biomedical Product and Materials Evaluation* (Woodhead
845 Publishing).

846 Arzuaga, X., M. T. Smith, C. F. Gibbons, N. E. Skakkebaek, E. E. Yost, B. E. J.
847 Beverly, A. K. Hotchkiss, R. Hauser, R. L. Pagani, S. M. Schrader, L. Zeise, and
848 G. S. Prins. 2019. 'Proposed Key Characteristics of Male Reproductive
849 Toxicants as an Approach for Organizing and Evaluating Mechanistic Evidence
850 in Human Health Hazard Assessments', *Environ Health Perspect*, 127: 65001.

851 ATSDR. 2021. 'Toxicological Profile for Perfluoroalkyls', Accessed 23 Dec 2022.
852 <https://wwwn.cdc.gov/TSP/ToxProfiles/ToxProfiles.aspx?id=1117&tid=237>.

853 Attina, Teresa M., Russ Hauser, Sheela Sathyanarayana, Patricia A. Hunt, Jean-Pierre
854 Bourguignon, John Peterson Myers, Joseph DiGangi, R. Thomas Zoeller, and
855 Leonardo Trasande. 2016. 'Exposure to endocrine-disrupting chemicals in the
856 USA: a population-based disease burden and cost analysis', *Lancet Diabetes
857 Endo*, 4: 996-1003.

858 Audouze, Karine, Denis Sarigiannis, Paloma Alonso-Magdalena, Celine Brochot,
859 Maribel Casas, Martine Vrijheid, Patrick J. Babin, Spyros Karakitsios, Xavier
860 Coumoul, and Robert Barouki. 2020. 'Integrative Strategy of Testing Systems
861 for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An
862 Introduction to the OBERON Project', *International Journal of Molecular
863 Sciences*, 21: 2988.

864 Auerbach, S., D. Filer, D. Reif, V. Walker, A. C. Holloway, J. Schlezinger, S.
865 Srinivasan, D. Svoboda, R. Judson, J. R. Bucher, and K. A. Thayer. 2016.
866 'Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes
867 Research: A Screening Approach Using ToxCast™ High-Throughput Data',
868 *Environ Health Perspect*, 124: 1141-54.

869 Bach, C., X. Dauchy, I. Severin, J. F. Munoz, S. Etienne, and M. C. Chagnon. 2013.
870 'Effect of temperature on the release of intentionally and non-intentionally added
871 substances from polyethylene terephthalate (PET) bottles into water: chemical
872 analysis and potential toxicity', *Food Chem*, 139: 672-80.

873 Bailey, George S., Ashok P. Reddy, Clifford B. Pereira, Ulrich Harttig, William Baird,
874 Jan M. Spitsbergen, Jerry D. Hendricks, Gayle A. Orner, David E. Williams, and
875 James A. Swenberg. 2009. 'Nonlinear Cancer Response at Ultralow Dose: A
876 40800-Animal ED001 Tumor and Biomarker Study', *Chemical Research in*
877 *Toxicology*, 22: 1264-76.

878 Barr, D. B., M. J. Silva, K. Kato, J. A. Reidy, N. A. Malek, D. Hurtz, M. Sadowski, L.
879 L. Needham, and A. M. Calafat. 2003. 'Assessing human exposure to phthalates
880 using monoesters and their oxidized metabolites as biomarkers', *Environ Health*
881 *Perspect*, 111: 1148-51.

882 Bauer, Anna, Florencia Jesús, María José Gómez Ramos, Ana Lozano, and Amadeo
883 Rodríguez Fernández-Alba. 2019. 'Identification of unexpected chemical
884 contaminants in baby food coming from plastic packaging migration by high
885 resolution accurate mass spectrometry', *Food Chemistry*, 295: 274-88.

886 Benbrahim-Tallaa, Lamia, Béatrice Lauby-Secretan, Dana Loomis, Kathryn Z. Guyton,
887 Yann Grosse, Fatiha El Ghissassi, Véronique Bouvard, Neela Guha, Heidi
888 Mattock, and Kurt Straif. 2014. 'Carcinogenicity of perfluorooctanoic acid,
889 tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane
890 sultone', *The Lancet Oncology*, 15: 924-25.

891 Beneventi, Elisa, Thomas Tietz, and Stefan Merkel. 2020. 'Risk Assessment of Food
892 Contact Materials', *EFSA Journal*, 18: e181109.

893 Bengtstrom, L., A. K. Rosenmai, X. Trier, L. K. Jensen, K. Granby, A. M. Vinggaard,
894 M. Driffield, and J. Hojslev Petersen. 2016. 'Non-targeted screening for
895 contaminants in paper and board food-contact materials using effect-directed
896 analysis and accurate mass spectrometry', *Food Addit Contam Part A Chem*
897 *Anal Control Expo Risk Assess*, 33: 1080-93.

898 Bennett, Deborah, David C. Bellinger, Linda S. Birnbaum, Asa Bradman, Aimin Chen,
899 Deborah A. Cory-Slechta, Stephanie M. Engel, M. Daniele Fallin, Alycia
900 Halladay, Russ Hauser, Irva Hertz-Picciotto, Carol F. Kwiatkowski, Bruce P.
901 Lanphear, Emily Marquez, Melanie Marty, Jennifer McPartland, Craig J.
902 Newschaffer, Devon Payne-Sturges, Heather B. Patisaul, Frederica P. Perera,
903 Beate Ritz, Jennifer Sass, Susan L. Schantz, Thomas F. Webster, Robin M.
904 Whyatt, Tracey J. Woodruff, R. Thomas Zoeller, Laura Anderko, Carla
905 Campbell, Jeanne A. Conry, Nathaniel DeNicola, Robert M. Gould, Deborah

906 Hirtz, Katie Huffling, Philip J. Landrigan, Arthur Lavin, Mark Miller, Mark A.
907 Mitchell, Leslie Rubin, Ted Schettler, Ho Luong Tran, Annie Acosta, Charlotte
908 Brody, Elise Miller, Pamela Miller, Maureen Swanson, and Nsedu Obot
909 Witherspoon. 2016. 'Project TENDR: Targeting Environmental Neuro-
910 Developmental Risks The TENDR Consensus Statement', *Environ Health*
911 *Perspect*, 124: A118-A22.

912 Bergman, Ake, Anna-Maria Andersson, Georg Becher, Martin van den Berg, Bruce
913 Blumberg, Poul Bjerregaard, Carl-Gustaf Bornehag, Riana Bornman, Ingvar
914 Brandt, Jayne Brian, Stephanie Casey, Paul Fowler, Heloise Frouin, Linda
915 Giudice, Taisen Iguchi, Ulla Hass, Susan Jobling, Anders Juul, Karen Kidd,
916 Andreas Kortenkamp, Monica Lind, Olwenn Martin, Derek Muir, Roseline
917 Ochieng, Nicolas Olea, Leif Norrgren, Erik Ropstad, Peter Ross, Christina
918 Ruden, and Martin Scheringer. 2013. 'Science and policy on endocrine
919 disrupters must not be mixed: a reply to a "common sense" intervention by
920 toxicology journal editors', *Environmental Health*, 12: 69.

921 Biedermann, Maurus, Jan-Erik Ingenhoff, Michael Zurfluh, Lydia Richter, Thomas
922 Simat, Antje Harling, Werner Altkofer, Rüdiger Helling, and Koni Grob. 2013.
923 'Migration of mineral oil, photoinitiators and plasticizers from recycled
924 paperboard into dry foods: a study under controlled conditions', *Food Additives*
925 *& Contaminants: Part A*: null-null.

926 Bil, W., E. Govarts, M. J. Zeilmaker, M. Woutersen, J. Bessems, Y. Ma, C. Thomsen,
927 L. S. Haug, S. Lignell, I. Gyllenhammar, L. Palkovicova Murinova, L. Fabelova,
928 J. Snoj Tratnik, T. Kosjek, C. Gabriel, D. Sarigiannis, S. Pedraza-Diaz, M.
929 Esteban-López, A. Castaño, L. Rambaud, M. Riou, C. Franken, A. Colles, N.
930 Vogel, M. Kolossa-Gehring, T. I. Halldorsson, M. Uhl, G. Schoeters, T.
931 Santonen, and A. M. Vinggaard. 2023. 'Approaches to mixture risk assessment
932 of PFASs in the European population based on human hazard and biomonitoring
933 data', *International Journal of Hygiene and Environmental Health*, 247: 114071.

934 Biryol, Derya, Chantel I. Nicolas, John Wambaugh, Katherine Phillips, and Kristin
935 Isaacs. 2017. 'High-throughput dietary exposure predictions for chemical
936 migrants from food contact substances for use in chemical prioritization',
937 *Environ Int*, 108: 185-94.

938 Blum, J., S. Masjosthusmann, K. Bartmann, F. Bendt, X. Dolde, A. Dönmez, N. Förster,
939 A. K. Holzer, U. Hübenthal, H. E. Keßel, S. Kilic, J. Klose, M. Pahl, L. C.
940 Stürzl, I. Mangas, A. Terron, K. M. Crofton, M. Scholze, A. Mosig, M. Leist,
941 and E. Fritsche. 2022. 'Establishment of a human cell-based in vitro battery to
942 assess developmental neurotoxicity hazard of chemicals', *Chemosphere*, 311:
943 137035.

944 Boisvert, Annie, Steven Jones, Leeyah Issop, Hanno C. Erythropel, Vassilios
945 Papadopoulos, and Martine Culty. 2016. 'In vitro functional screening as a
946 means to identify new plasticizers devoid of reproductive toxicity',
947 *Environmental Research*, 150: 496-512.

948 Boomsma, C. M., M. J. Eijkemans, E. G. Hughes, G. H. Visser, B. C. Fauser, and N. S.
949 Macklon. 2006. 'A meta-analysis of pregnancy outcomes in women with
950 polycystic ovary syndrome', *Hum Reprod Update*, 12: 673-83.

951 Bornehag, Carl-Gustaf, Elin Engdahl, Maria Unenge Hallerbäck, Sverre Wikström,
952 Christian Lindh, Joëlle Rüegg, Eva Tanner, and Chris Gennings. 2021. 'Prenatal
953 exposure to bisphenols and cognitive function in children at 7 years of age in the
954 Swedish SELMA study', *Environ Int*, 150: 106433.

955 Bornehag, Carl-Gustaf, Efthymia Kitraki, Antonios Stamatakis, Emily Panagiotidou,
956 Christina Rudén, Huan Shu, Christian Lindh, Joelle Ruegg, and Chris Gennings.
957 2019. 'A Novel Approach to Chemical Mixture Risk Assessment—Linking Data
958 from Population-Based Epidemiology and Experimental Animal Tests', *Risk*
959 *Analysis*, 39: 2259-71.

960 Bradley, E. L., M. Driffield, N. Harmer, P. K. T. Oldring, and L. Castle. 2008.
961 'Identification of potential migrants in epoxy phenolic can coatings', *Int. J.*
962 *Polym. Anal. Charact.* , 13: 200-23.

963 Bradley, Emma, and L Coulier. 2007. "An investigation into the reaction and
964 breakdown products from starting substances used to produce food contact
965 plastics." In, edited by Food Standards Agency. London: Central Science
966 Laboratory.

967 Bschor, Karim. accepted. 'Risk, Uncertainty and Precaution in Science: The case of the
968 Threshold of Toxicological Concern Approach in Food Toxicology', *J Sci Eng*
969 *Ethics*.

970 Buckley, J. P., S. M. Engel, J. M. Braun, R. M. Whyatt, J. L. Daniels, M. A. Mendez, D.
971 B. Richardson, Y. Xu, A. M. Calafat, M. S. Wolff, B. P. Lanphear, A. H.
972 Herring, and A. G. Rundle. 2016. 'Prenatal Phthalate Exposures and Body Mass
973 Index Among 4- to 7-Year-old Children: A Pooled Analysis', *Epidemiology*, 27:
974 449-58.

975 Caffrey, T. M., E. B. Button, and J. Robert. 2021. 'Toward three-dimensional in vitro
976 models to study neurovascular unit functions in health and disease', *Neural
977 Regen Res*, 16: 2132-40.

978 Calafat, A., Z. Kuklennyik, J. A. Reidy, S. P. Caudill, J. Ekong, and L. L. Needham.
979 2005. 'Urinary Concentrations of Bisphenol A and 4-Nonylphenol in a Human
980 Reference Population', *Environ Health Perspect*, 113: 391-95.

981 Caporale, Nicolò, Michelle Leemans, Lina Birgersson, Pierre-Luc Germain, Cristina
982 Cheroni, Gábor Borbély, Elin Engdahl, Christian Lindh, Raul Bardini Bressan,
983 Francesca Cavallo, Nadav Even Chorev, Giuseppe Alessandro D'Agostino,
984 Steven M. Pollard, Marco Tullio Rigoli, Erika Tenderini, Alejandro Lopez
985 Tobon, Sebastiano Trattaro, Flavia Troglio, Matteo Zanella, Åke Bergman,
986 Pauliina Damdimopoulou, Maria Jönsson, Wieland Kiess, Efthymia Kitraki,
987 Hannu Kiviranta, Eewa Nånberg, Mattias Öberg, Panu Rantakokko, Christina
988 Rudén, Olle Söder, Carl-Gustaf Bornehag, Barbara Demeneix, Jean-Baptiste
989 Fini, Chris Gennings, Joëlle Rüegg, Joachim Sturve, and Giuseppe Testa. 2022.
990 'From cohorts to molecules: Adverse impacts of endocrine disrupting mixtures',
991 *Science*, 375: eabe8244.

992 Castle, L., A. Mayo, C. Crews, and J. Gilbert. 1989. 'Migration of Poly(ethylene
993 terephthalate) (PET) Oligomers from PET Plastics into Foods during Microwave
994 and Conventional Cooking and into Bottled Beverages', *J Food Prot.*, 52: 337-
995 42.

996 Cediel-Ulloa, Andrea, Diana Loana Lupu, Ylva Johansson, Maria Hinojosa, Fatih Özel,
997 and Joëlle Rüegg. 2022. 'Impact of endocrine disrupting chemicals on
998 neurodevelopment: the need for better testing strategies for endocrine
999 disruption-induced developmental neurotoxicity', *Expert Review of
1000 Endocrinology & Metabolism*, 17: 131-41.

1001 Chakori, Sabrina, Ammar Abdul Aziz, Carl Smith, and Paul Dargusch. 2021.
1002 'Untangling the underlying drivers of the use of single-use food packaging',
1003 *Ecological Economics*, 185: 107063.

1004 Chamorro-Garcia, R., and B. Blumberg. 2019. 'Current Research Approaches and
1005 Challenges in the Obesogen Field', *Front Endocrinol (Lausanne)*, 10: 167.

1006 Chamorro-Garcia, R., C. Diaz-Castillo, B. M. Shoucri, H. Käch, R. Leavitt, T. Shioda,
1007 and B. Blumberg. 2017. 'Ancestral perinatal obesogen exposure results in a
1008 transgenerational thrifty phenotype in mice', *Nat Commun*, 8: 2012.

1009 Charazac, A., C. Hinault, B. Dolfi, S. Hautier, C. Decondé Le Butor, F. Bost, and N.
1010 Chevalier. 2022. 'Low Doses of PFOA Promote Prostate and Breast Cancer
1011 Cells Growth through Different Pathways', *Int J Mol Sci*, 23.

1012 Chiara, Federica, Stefano Indraccolo, and Andrea Trevisan. 2020. 'Filling the gap
1013 between risk assessment and molecular determinants of tumor onset',
1014 *Carcinogenesis*, 42: 507-16.

1015 CIPA. 2019. 'CIPA Initiative', Accessed 23 Dec 2022. <https://cipaproject.org/>.

1016 Cooper, B. L., and N. G. Posnack. 2022. 'Characteristics of Bisphenol Cardiotoxicity:
1017 Impaired Excitability, Contractility, and Relaxation', *Cardiovasc Toxicol*, 22:
1018 273-80.

1019 Correia-Sá, Luísa, André Schütze, Sónia Norberto, Conceição Calhau, Valentina F.
1020 Domingues, and Holger M. Koch. 2017. 'Exposure of Portuguese children to the
1021 novel non-phthalate plasticizer di-(iso-nonyl)-cyclohexane-1,2-dicarboxylate
1022 (DINCH)', *Environ Int*, 102: 79-86.

1023 Corsini, Emanuela, and Erwin L. Roggen. 2017. 'Overview of in vitro assessment of
1024 immunotoxicity', *Current Opinion in Toxicology*, 5: 13-18.

1025 Cortéjade, Aurélie, Audrey Buleté, Laura Prouteau, Saber Chatti, Cécile Cren, and
1026 Emmanuelle Vulliet. 2017. 'Development and optimisation of home-made stir
1027 bar sorptive extraction for analysis of plastic additives: application in human
1028 urine', *Analytical Methods*, 9: 3549-60.

1029 Corton, J. C., J. Liu, N. Kleinstreuer, M. R. Gwinn, and N. Ryan. 2022. 'Towards
1030 replacement of animal tests with in vitro assays: a gene expression biomarker
1031 predicts in vitro and in vivo estrogen receptor activity', *Chem Biol Interact*, 363:
1032 109995.

1033 Coumoul, Xavier, Robert Barouki, Meriem Koual, Karine Audouze, and Celine
1034 Tomkiewicz. 2022. 'Activation of the AhR leading to breast cancer. AOP 439',
1035 Accessed 23 Dec 2022. <https://aopwiki.org/aops/439>.

1036 Dales, Robert Edgar, Lisa Marie Kauri, and Sabit Cakmak. 2018. 'The associations
1037 between phthalate exposure and insulin resistance, β -cell function and blood
1038 glucose control in a population-based sample', *Science of The Total
1039 Environment*, 612: 1287-92.

1040 Demeneix, B.A., and R. Slama. 2019. "Endocrine Disruptors: From the scientific
1041 evidence to human health protection." In *Report to the European Parliament*. .
1042 European Parliament.

1043 Deprouw, C., A. Courties, J. B. Fini, M. S. Clerget-Froidevaux, B. Demeneix, F.
1044 Berenbaum, J. Sellam, and K. Louati. 2022. 'Pollutants: a candidate as a new
1045 risk factor for osteoarthritis-results from a systematic literature review', *RMD
1046 Open*, 8.

1047 Desai, M., M. G. Ferrini, G. Han, J. K. Jellyman, and M. G. Ross. 2018a. 'In vivo
1048 maternal and in vitro BPA exposure effects on hypothalamic neurogenesis and
1049 appetite regulators', *Environ Res*, 164: 45-52.

1050 Desai, M., M. G. Ferrini, J. K. Jellyman, G. Han, and M. G. Ross. 2018b. 'In vivo and in
1051 vitro bisphenol A exposure effects on adiposity', *J Dev Orig Health Dis*, 9: 678-
1052 87.

1053 Desmarchais, Alice, Ophélie Têteau, Pascal Papillier, Manon Jaubert, Xavier Druart,
1054 Aurélien Binet, Virginie Maillard, and Sebastien Elis. 2020. 'Bisphenol S
1055 Impaired In Vitro Ovine Early Developmental Oocyte Competence',
1056 *International Journal of Molecular Sciences*, 21: 1238.

1057 DeWitt, Jamie C., Sarah J. Blossom, and Laurel A. Schaidler. 2019. 'Exposure to per-
1058 fluoroalkyl and polyfluoroalkyl substances leads to immunotoxicity:
1059 epidemiological and toxicological evidence', *J Expo Sci Environ Epidemiol*, 29:
1060 148-56.

1061 Dhimolea, E., P. R. Wadia, T. J. Murray, M. L. Settles, J. D. Treitman, C.
1062 Sonnenschein, T. Shioda, and A. M. Soto. 2014. 'Prenatal exposure to BPA
1063 alters the epigenome of the rat mammary gland and increases the propensity to
1064 neoplastic development', *PLoS One*, 9: e99800.

1065 Dionisi, G., and P. K. Oldring. 2002. 'Estimates of per capita exposure to substances
1066 migrating from canned foods and beverages', *Food Addit Contam*, 19: 891-903.

1067 Domínguez-Romero, Elena, Klára Komprdová, Jiří Kalina, Jos Bessems, Spyros
1068 Karakitsios, Dimosthenis A. Sarigiannis, and Martin Scheringer. 2022. 'Time-
1069 trends in human urinary concentrations of phthalates and substitutes DEHT and
1070 DINCH in Asian and North American countries (2009–2019)', *J Expo Sci*
1071 *Environ Epidemiol*.

1072 Dos Santos, Reinaldo Sousa, Regla María Medina-Gali, Ignacio Babiloni-Chust, Laura
1073 Marroqui, and Angel Nadal. 2022. 'In Vitro Assays to Identify Metabolism-
1074 Disrupting Chemicals with Diabetogenic Activity in a Human Pancreatic
1075 β-Cell Model', *International Journal of Molecular Sciences*, 23: 5040.

1076 Eales, J., A. Bethel, T. Galloway, P. Hopkinson, K. Morrissey, R. E. Short, and R.
1077 Garside. 2022. 'Human health impacts of exposure to phthalate plasticizers: An
1078 overview of reviews', *Environ Int*, 158: 106903.

1079 EFSA. 2008. 'Guidance document on the submission of a dossier on a substance to be
1080 used in Food Contact Materials for evaluation by EFSA by the Panel on
1081 additives, flavourings, processing aids and materials in contact with food
1082 (AFC)', *EFSA Journal*.

1083 El-Kersh, Karim, C. Danielle Hopkins, Xiaoyong Wu, Shesh N. Rai, Lu Cai, and
1084 Jiapeng Huang. 2022. 'Plasma level of antimony correlates with pulmonary
1085 arterial hypertension severity', *Current Research in Toxicology*, 3: 100080.

1086 Escher, B. I., and P. A. Neale. 2021. 'Effect-Based Trigger Values for Mixtures of
1087 Chemicals in Surface Water Detected with In Vitro Bioassays', *Environ Toxicol*
1088 *Chem*, 40: 487-99.

1089 Escher, B. I., P. A. Neale, and F. D. Leusch. 2015. 'Effect-based trigger values for
1090 in vitro bioassays: Reading across from existing water quality guideline values',
1091 *Water Res*, 81: 137-48.

1092 Escher, Beate I., Selim Ait-Aïssa, Peter A. Behnisch, Werner Brack, François Brion,
1093 Abraham Brouwer, Sebastian Buchinger, Sarah E. Crawford, David Du
1094 Pasquier, Timo Hamers, Karina Hettwer, Klára Hilscherová, Henner Hollert,
1095 Robert Kase, Cornelia Kienle, Andrew J. Tindall, Jochen Tuerk, Ron van der
1096 Oost, Etienne Vermeirssen, and Peta A. Neale. 2018. 'Effect-based trigger
1097 values for in vitro and in vivo bioassays performed on surface water extracts

1098 supporting the environmental quality standards (EQS) of the European Water
1099 Framework Directive', *Science of The Total Environment*, 628-629: 748-65.

1100 Estill, Molly, Russ Hauser, Feiby L. Nassan, Alan Moss, and Stephen A. Krawetz.
1101 2019. 'The effects of di-butyl phthalate exposure from medications on human
1102 sperm RNA among men', *Scientific Reports*, 9: 12397.

1103 EU. 2011. "COMMISSION REGULATION (EU) No 10/2011 of 14 January 2011 on
1104 plastic materials and articles intended to come into contact with food." In *EU*
1105 *10/2011*, edited by European Union. Brussels: European Union.

1106 ———. 2020a. "Chemicals Strategy for Sustainability. Towards a Toxic-Free
1107 Environment." In.: European Commission.

1108 ———. 2020b. "A Farm to Fork Strategy for a fair, healthy and environmentally-
1109 friendly food system." In.: European Commission.

1110 European Chemicals Agency. 2017. "Read-Across Assessment Framework (RAAF)."
1111 In.: European Chemicals Agency.

1112 European Parliament. 2016. "Implementation of the Food Contact Materials Regulation.
1113 European Parliament resolution of 6 October 2016 on the implementation of the
1114 Food Contact Materials Regulation (EC) No 1935/2004 (2015/2259(INI))." In.

1115 FDA. 2007. 'Guidance for Industry: Preparation of Premarket Submissions for Food
1116 Contact Substances: Chemistry Recommendations.', Accessed 23 December
1117 2022. [https://www.fda.gov/regulatory-information/search-fda-guidance-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry)
1118 [documents/guidance-industry-preparation-premarket-submissions-food-contact-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry)
1119 [substances-chemistry](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry).

1120 ———. 2022. 'Impact Story: Improved Assessment of Cardiotoxic Risk in Drug
1121 Candidates: The Comprehensive in vitro Proarrhythmia Assay', Accessed 23
1122 Dec 2022. [https://www.fda.gov/drugs/regulatory-science-action/impact-story-](https://www.fda.gov/drugs/regulatory-science-action/impact-story-improved-assessment-cardiotoxic-risk-drug-candidates-comprehensive-vitro-proarrhythmia)
1123 [improved-assessment-cardiotoxic-risk-drug-candidates-comprehensive-vitro-](https://www.fda.gov/drugs/regulatory-science-action/impact-story-improved-assessment-cardiotoxic-risk-drug-candidates-comprehensive-vitro-proarrhythmia)
1124 [proarrhythmia](https://www.fda.gov/drugs/regulatory-science-action/impact-story-improved-assessment-cardiotoxic-risk-drug-candidates-comprehensive-vitro-proarrhythmia).

1125 Feil, Robert, and Mario F. Fraga. 2012. 'Epigenetics and the environment: emerging
1126 patterns and implications', *Nature Reviews Genetics*, 13: 97-109.

1127 Fenner, K., and M. Scheringer. 2021. 'The Need for Chemical Simplification As a
1128 Logical Consequence of Ever-Increasing Chemical Pollution', *Environ Sci*
1129 *Technol*, 55: 14470-72.

1130 Filer, D. L., K. Hoffman, R. M. Sargis, L. Trasande, and C. D. Kassotis. 2022. 'On the
1131 Utility of ToxCast-Based Predictive Models to Evaluate Potential Metabolic
1132 Disruption by Environmental Chemicals', *Environ Health Perspect*, 130: 57005.

1133 Fitz-James, Maximilian H., and Giacomo Cavalli. 2022. 'Molecular mechanisms of
1134 transgenerational epigenetic inheritance', *Nature Reviews Genetics*, 23: 325-41.

1135 Fitzgerald, Jennifer A., Sarah Könemann, Laura Krümpelmann, Anže Županič, and
1136 Colette vom Berg. 2021. 'Approaches to Test the Neurotoxicity of
1137 Environmental Contaminants in the Zebrafish Model: From Behavior to
1138 Molecular Mechanisms', *Environmental Toxicology and Chemistry*, 40: 989-
1139 1006.

1140 Foresta, C., S. Tescari, and A. Di Nisio. 2018. 'Impact of perfluorochemicals on human
1141 health and reproduction: a male's perspective', *J Endocrinol Invest*, 41: 639-45.

1142 Friedman, Katie Paul, Kevin Crofton, and Mary Gilbert. 2022. 'Upregulation of Thyroid
1143 Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and
1144 Subsequent Adverse Neurodevelopmental Outcomes in Mammals. AOP 8',
1145 Accessed 23 Dec 2022. <https://aopwiki.org/aops/8>.

1146 Fu, Xiangjun, Jie Xu, Renyi Zhang, and Jie Yu. 2020. 'The association between
1147 environmental endocrine disruptors and cardiovascular diseases: A systematic
1148 review and meta-analysis', *Environmental Research*, 187: 109464.

1149 Gao, X., and H. S. Wang. 2014. 'Impact of bisphenol a on the cardiovascular system -
1150 epidemiological and experimental evidence and molecular mechanisms', *Int J
1151 Environ Res Public Health*, 11: 8399-413.

1152 Garcia-Calvo, E., A. Machuca, C. Nerín, N. Rosales-Conrado, D. S. Anunciação, and J.
1153 L. Luque-Garcia. 2020a. 'Integration of untargeted and targeted mass
1154 spectrometry-based metabolomics provides novel insights into the potential
1155 toxicity associated to surfynol', *Food Chem Toxicol*, 146: 111849.

1156 Garcia-Calvo, Estefania, Andres Machuca, Cristina Nerín, Noelia Rosales-Conrado,
1157 Daniela S. Anunciação, and Jose L. Luque-Garcia. 2020b. 'Integration of
1158 untargeted and targeted mass spectrometry-based metabolomics provides novel
1159 insights into the potential toxicity associated to surfynol', *Food and Chemical
1160 Toxicology*, 146: 111849.

1161 Gascon, Mireia, Maribel Casas, Eva Morales, Damaskini Valvi, Ana Ballesteros-
1162 Gómez, Noelia Luque, Soledad Rubio, Núria Monfort, Rosa Ventura, David

1163 Martínez, Jordi Sunyer, and Martine Vrijheid. 2015. 'Prenatal exposure to
1164 bisphenol A and phthalates and childhood respiratory tract infections and
1165 allergy', *Journal of Allergy and Clinical Immunology*, 135: 370-78.e7.

1166 Gear, R., J. A. Kendzioriski, and S. M. Belcher. 2017. 'Effects of bisphenol A on
1167 incidence and severity of cardiac lesions in the NCTR-Sprague-Dawley rat: A
1168 CLARITY-BPA study', *Toxicol Lett*, 275: 123-35.

1169 Geiger, S. D., P. Yao, M. G. Vaughn, and Z. Qian. 2021. 'PFAS exposure and
1170 overweight/obesity among children in a nationally representative sample',
1171 *Chemosphere*, 268: 128852.

1172 Germolec, D., R. Luebke, A. Rooney, K. Shipkowski, R. Vandebriel, and H. van
1173 Loveren. 2017. 'Immunotoxicology: A brief history, current status and strategies
1174 for future immunotoxicity assessment', *Curr Opin Toxicol*, 5: 55-59.

1175 Germolec, D. R., H. Lebec, S. E. Anderson, G. R. Burleson, A. Cardenas, E. Corsini,
1176 S. E. Elmore, B. L. F. Kaplan, B. P. Lawrence, G. M. Lehmann, C. C. Maier, C.
1177 M. McHale, L. P. Myers, M. Pallardy, A. A. Rooney, L. Zeise, L. Zhang, and M.
1178 T. Smith. 2022. 'Consensus on the Key Characteristics of Immunotoxic Agents
1179 as a Basis for Hazard Identification', *Environ Health Perspect*, 130: 105001.

1180 Geueke, B. 2018. "Non-intentionally added substances (NIAS)." In *FPF Dossier*, edited
1181 by Food Packaging Forum. Food Packaging Forum Foundation.

1182 Geueke, Birgit, Ksenia J. Groh, Maricel V. Maffini, Olwenn V. Martin, Justin M.
1183 Boucher, Yu-Ting Chiang, Frank Gwosdz, Phoenix Jieh, Christopher D.
1184 Kassotis, Paulina Łańska, John Peterson Myers, Alex Odermatt, Lindsey V.
1185 Parkinson, Verena N. Schreier, Vanessa Srebny, Lisa Zimmermann, Martin
1186 Scheringer, and Jane Muncke. 2022. 'Systematic evidence on migrating and
1187 extractable food contact chemicals: Most chemicals detected in food contact
1188 materials are not listed for use', *Critical Reviews in Food Science and Nutrition*:
1189 1-11.

1190 Geueke, Birgit, Ksenia Groh, and Jane Muncke. 2018. 'Food packaging in the circular
1191 economy: Overview of chemical safety aspects for commonly used materials',
1192 *Journal of Cleaner Production*, 193: 491-505.

1193 Geueke, Birgit, Drake W. Phelps, Lindsey V. Parkinson, and Jane Muncke. 2023.
1194 'Hazardous chemicals in recycled and reusable plastic food packaging',
1195 *Cambridge Prisms: Plastics*, 1: e7.

1196 Goralczyk, Katarzyna. 2021. "A Review of the Impact of Selected Anthropogenic
1197 Chemicals from the Group of Endocrine Disruptors on Human Health." In
1198 *Toxics*.

1199 Gore, A. C., V. A. Chappell, S. E. Fenton, J. A. Flaws, A. Nadal, G. S. Prins, J. Toppari,
1200 and R. T. Zoeller. 2015. 'EDC-2: The Endocrine Society's Second Scientific
1201 Statement on Endocrine-Disrupting Chemicals', *Endocrine Reviews*, 36: E1-
1202 E150.

1203 Grandjean, P., and P. J. Landrigan. 2006. 'Developmental neurotoxicity of industrial
1204 chemicals', *Lancet*, 368: 2167-78.

1205 Grandjean, Philippe, Carsten Heilmann, Pal Weihe, Flemming Nielsen, Ulla B.
1206 Mogensen, Amalie Timmermann, and Esben Budtz-Jørgensen. 2017. 'Estimated
1207 exposures to perfluorinated compounds in infancy predict attenuated vaccine
1208 antibody concentrations at age 5-years', *Journal of Immunotoxicology*, 14: 188-
1209 95.

1210 Grob, K., M. Biedermann, E. Scherbaum, M. Roth, and K. Rieger. 2006. 'Food
1211 contamination with organic materials in perspective: packaging materials as the
1212 largest and least controlled source? A view focusing on the European situation',
1213 *Crit Rev Food Sci Nutr*, 46: 529-35.

1214 Groh, Ksenia J., Birgit Geueke, Olwenn Martin, Maricel Maffini, and Jane Muncke.
1215 2021. 'Overview of intentionally used food contact chemicals and their hazards',
1216 *Environ Int*, 150: 106225.

1217 Groh, Ksenia J., and Jane Muncke. 2017. 'In Vitro Toxicity Testing of Food Contact
1218 Materials: State-of-the-Art and Future Challenges', *COMPREHENSIVE
1219 REVIEWS IN FOOD SCIENCE AND FOOD SAFETY*, 16: 1123–50.

1220 Guyton, Kathryn Z, Ivan Rusyn, Weihsueh A Chiu, Denis E Corpet, Martin van den
1221 Berg, Matthew K Ross, David C Christiani, Frederick A Beland, and Martyn T
1222 Smith. 2018. 'Application of the key characteristics of carcinogens in cancer
1223 hazard identification', *Carcinogenesis*, 39: 614-22.

1224 Guyton, Kathryn Z., and Mary K. Schubauer-Berigan. 2021. 'Invited Perspective:
1225 Prioritizing Chemical Testing and Evaluation Using Validated in Vitro Assays
1226 Relevant to Key Characteristics', *Environ Health Perspect*, 129: 071303.

1227 Hager, E., J. Chen, and L. Zhao. 2022. 'Minireview: Parabens Exposure and Breast
1228 Cancer', *Int J Environ Res Public Health*, 19.

1229 He, X., Y. Liu, B. Xu, L. Gu, and W. Tang. 2018. 'PFOA is associated with diabetes
1230 and metabolic alteration in US men: National Health and Nutrition Examination
1231 Survey 2003-2012', *Sci Total Environ*, 625: 566-74.

1232 Heindel, J. J. 2019. 'History of the Obesogen Field: Looking Back to Look Forward',
1233 *Front Endocrinol (Lausanne)*, 10: 14.

1234 Heindel, J. J., S. Howard, K. Agay-Shay, J. P. Arrebola, K. Audouze, P. J. Babin, R.
1235 Barouki, A. Bansal, E. Blanc, M. C. Cave, S. Chatterjee, N. Chevalier, M.
1236 Choudhury, D. Collier, L. Connolly, X. Coumoul, G. Garruti, M. Gilbertson, L.
1237 A. Hoepner, A. C. Holloway, G. Howell, 3rd, C. D. Kassotis, M. K. Kay, M. J.
1238 Kim, D. Lagadic-Gossman, S. Langouet, A. Legrand, Z. Li, H. Le Mentec, L.
1239 Lind, P. Monica Lind, R. H. Lustig, C. Martin-Chouly, V. Munic Kos, N.
1240 Podechard, T. A. Roepke, R. M. Sargis, A. Starling, C. R. Tomlinson, C.
1241 Touma, J. Vondracek, F. Vom Saal, and B. Blumberg. 2022. 'Obesity II:
1242 Establishing causal links between chemical exposures and obesity', *Biochem*
1243 *Pharmacol*, 199: 115015.

1244 Hessel, Ellen V. S., Elisa C. M. Tonk, Peter M. J. Bos, Henk van Loveren, and Aldert
1245 H. Piersma. 2015. 'Developmental immunotoxicity of chemicals in rodents and
1246 its possible regulatory impact', *Critical Reviews in Toxicology*, 45: 68-82.

1247 Hlisníková, H., I. Petrovičová, B. Kolena, M. Šidlovská, and A. Sirotkin. 2021. 'Effects
1248 and mechanisms of phthalates' action on neurological processes and neural
1249 health: a literature review', *Pharmacol Rep*, 73: 386-404.

1250 Horodytska, O., A. Cabanes, and A. Fullana. 2020. 'Non-intentionally added substances
1251 (NIAS) in recycled plastics', *Chemosphere*, 251: 126373.

1252 Hsieh, T. J., P. C. Hsieh, Y. H. Tsai, C. F. Wu, C. C. Liu, M. Y. Lin, and M. T. Wu.
1253 2012. 'Melamine induces human renal proximal tubular cell injury via
1254 transforming growth factor- β and oxidative stress', *Toxicol Sci*, 130: 17-32.

1255 Huff, James, Michael F. Jacobson, and Devra Lee Davis. 2008. 'The Limits of Two-
1256 Year Bioassay Exposure Regimens for Identifying Chemical Carcinogens',
1257 *Environ Health Perspect*, 116: 1439-42.

1258 Hunt, Piper Reid, Nicholas Olejnik, Keenan D. Bailey, Cory A. Vaught, and Robert L.
1259 Sprando. 2018. 'C. elegans Development and Activity Test detects mammalian
1260 developmental neurotoxins', *Food and Chemical Toxicology*, 121: 583-92.

1261 Hwang, S. H., H. Yeom, B. I. Han, B. J. Ham, Y. M. Lee, M. R. Han, and M. Lee. 2020.
1262 'Predicting Carcinogenic Mechanisms of Non-Genotoxic Carcinogens via
1263 Combined Analysis of Global DNA Methylation and In Vitro Cell
1264 Transformation', *Int J Mol Sci*, 21.

1265 Hyun, S. A., C. Y. Lee, M. Y. Ko, S. H. Chon, Y. J. Kim, J. W. Seo, K. K. Kim, and M.
1266 Ka. 2021. 'Cardiac toxicity from bisphenol A exposure in human-induced
1267 pluripotent stem cell-derived cardiomyocytes', *Toxicol Appl Pharmacol*, 428:
1268 115696.

1269 IARC. 2010. "Some Aromatic Amines, Organic Dyes, and Related Exposures. IARC
1270 Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 99."
1271 In *IARC Monographs*, edited by International Agency for Research on Cancer.
1272 Lyon, France: IARC.

1273 ———. 2012a. "Chemical Agents and Related Occupations. IARC Monographs on the
1274 Evaluation of Carcinogenic Risks to Humans Volume 100F." In *IARC*
1275 *Monographs*, edited by International Agency for Research on Cancer. Lyon,
1276 France: International Agency for Research on Cancer.

1277 ———. 2012b. "Some Chemicals Present in Industrial and Consumer Products, Food
1278 and Drinking-water. IARC Monographs on the Evaluation of Carcinogenic
1279 Risks to Humans Volume 101." In *IARC Monographs*, edited by International
1280 Agency for Research on Cancer. Lyon, France: IARC.

1281 ———. 2016. "Some Chemicals Used as Solvents and in Polymer Manufacture. IARC
1282 Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 110."
1283 In *IARC Monographs*, edited by International Agency for Research on Cancer.
1284 Lyon, France.

1285 ———. 2019. "Some Chemicals That Cause Tumours of the Urinary Tract in Rodents.
1286 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume
1287 119." In *IARC Monographs*, edited by International Agency for Research on
1288 Cancer. Lyon, France.

1289 ———. 2022. "Agents classified by the IARC monographs, volumes 1–129." In, edited
1290 by International Agency for Research on Cancer.
1291 <https://monographs.iarc.who.int/agents-classified-by-the-iarc/>.

1292 Isaacs, K. K., J. T. Wall, A. R. Williams, K. A. Hobbie, J. R. Sobus, E. Ulrich, D.
1293 Lyons, K. L. Dionisio, A. J. Williams, C. Grulke, C. A. Foster, J. McCoy, and C.

1294 Bevington. 2022. 'A harmonized chemical monitoring database for support of
1295 exposure assessments', *Sci Data*, 9: 314.

1296 Janesick, A. S., G. Dimastrogiovanni, L. Vanek, C. Boulos, R. Chamorro-García, W.
1297 Tang, and B. Blumberg. 2016. 'On the Utility of ToxCast™ and ToxPi as
1298 Methods for Identifying New obesogens', *Environ Health Perspect*, 124: 1214-
1299 26.

1300 Jickells, S. M., P. Gancedo, C. Nerin, L. Castle, and J. Gilbert. 1993. 'Migration of
1301 styrene monomer from thermoset polyester cookware into foods during high
1302 temperature applications', *Food Addit Contam*, 10: 567-73.

1303 Jokinen, M. P., W. G. Lieuallen, C. L. Johnson, J. Dunnick, and A. Nyska. 2005.
1304 'Characterization of spontaneous and chemically induced cardiac lesions in
1305 rodent model systems: the national toxicology program experience', *Cardiovasc*
1306 *Toxicol*, 5: 227-44.

1307 Jokinen, Micheal P., Warren G. Lieuallen, Michael C. Boyle, Crystal L. Johnson, David
1308 E. Malarkey, and Abraham Nyska. 2011. 'Morphologic Aspects of Rodent
1309 Cardiotoxicity in a Retrospective Evaluation of National Toxicology Program
1310 Studies', *Toxicologic Pathology*, 39: 850-60.

1311 Jorgensen, A., T. Svingen, H. Miles, T. Chetty, J. B. Stukenborg, and R. T. Mitchell.
1312 2021. 'Environmental Impacts on Male Reproductive Development: Lessons
1313 from Experimental Models', *Hormone Research in Paediatrics*.

1314 Jun, J. H., J. E. Oh, J. K. Shim, Y. L. Kwak, and J. S. Cho. 2021. 'Effects of bisphenol
1315 A on the proliferation, migration, and tumor growth of colon cancer cells: In
1316 vitro and in vivo evaluation with mechanistic insights related to ERK and 5-
1317 HT3', *Food Chem Toxicol*, 158: 112662.

1318 Jung, S. K., W. Choi, S. Y. Kim, S. Hong, H. L. Jeon, Y. Joo, C. Lee, K. Choi, S. Kim,
1319 K. J. Lee, and J. Yoo. 2022. 'Profile of Environmental Chemicals in the Korean
1320 Population-Results of the Korean National Environmental Health Survey
1321 (KoNEHS) Cycle 3, 2015-2017', *Int J Environ Res Public Health*, 19.

1322 Kassotis, C. D., and H. M. Stapleton. 2019. 'Endocrine-Mediated Mechanisms of
1323 Metabolic Disruption and New Approaches to Examine the Public Health
1324 Threat', *Front Endocrinol (Lausanne)*, 10: 39.

1325 Kassotis, C. D., F. S. Vom Saal, P. J. Babin, D. Lagadic-Gossmann, H. Le Mentec, B.
1326 Blumberg, N. Mohajer, A. Legrand, V. Munic Kos, C. Martin-Chouly, N.

1327 Podechard, S. Langouët, C. Touma, R. Barouki, M. J. Kim, K. Audouze, M.
1328 Choudhury, N. Shree, A. Bansal, S. Howard, and J. J. Heindel. 2022. 'Obesity
1329 III: Obesogen assays: Limitations, strengths, and new directions', *Biochem*
1330 *Pharmacol*, 199: 115014.

1331 Kassotis, Christopher D., Laura N. Vandenberg, Barbara A. Demeneix, Miquel Porta,
1332 Remy Slama, and Leonardo Trasande. 2020. 'Endocrine-disrupting chemicals:
1333 economic, regulatory, and policy implications', *The Lancet Diabetes &*
1334 *Endocrinology*, 8: 719-30.

1335 Keri, Ruth A., Shuk-Mei Ho, Patricia A. Hunt, Karen E. Knudsen, Ana M. Soto, and
1336 Gail S. Prins. 2007. 'An Evaluation of Evidence for the Carcinogenic Activity of
1337 Bisphenol A', *Reprod Tox*, 24: 240-52.

1338 Key Characteristics. 2022. 'Key Characteristics. Identifying the Key Characteristics of
1339 Hazardous Chemicals and Other Exposures: A Collaborative Approach',
1340 Accessed 23 Dec 2022. <https://keycharacteristics.org/>.

1341 Kilic, O., D. Pamies, E. Lavell, P. Schiapparelli, Y. Feng, T. Hartung, A. Bal-Price, H.
1342 T. Hogberg, A. Quinones-Hinojosa, H. Guerrero-Cazares, and A. Levchenko.
1343 2016. 'Brain-on-a-chip model enables analysis of human neuronal differentiation
1344 and chemotaxis', *Lab Chip*, 16: 4152-62.

1345 Kim, E. H., B. H. Jeon, J. Kim, Y. M. Kim, Y. Han, K. Ahn, and H. K. Cheong. 2017.
1346 'Exposure to phthalates and bisphenol A are associated with atopic dermatitis
1347 symptoms in children: a time-series analysis', *Environ Health*, 16: 24.

1348 Kim, Hyung Soo, Ye Jin Lee, Ye Ji Koo, Eun Chul Pack, Kyung Min Lim, and Dal
1349 Woong Choi. 2021. 'Migration of monomers, plastic additives, and non-
1350 intentionally added substances from food utensils made of melamine–
1351 formaldehyde resin following ultraviolet sterilization', *Food Control*, 125:
1352 107981.

1353 Kim, Johanna Inhyang, Young Ah Lee, Choong Ho Shin, Yun-Chul Hong, Bung-Nyun
1354 Kim, and Youn-Hee Lim. 2022. 'Association of bisphenol A, bisphenol F, and
1355 bisphenol S with ADHD symptoms in children', *Environ Int*, 161: 107093.

1356 Kirk, Andrea B. 2006. 'Environmental perchlorate: Why it matters', *Analytica Chimica*
1357 *Acta*, 567: 4-12.

1358 Koch, H. M., and A. M. Calafat. 2009. 'Human body burdens of chemicals used in
1359 plastic manufacture', *Philos Trans R Soc Lond B Biol Sci*, 364: 2063-78.

1360 Kofron, Celinda M., Tae Yun Kim, Fabiola Munarin, Arvin H. Soepriatna, Rajeev J.
1361 Kant, Ulrike Mende, Bum-Rak Choi, and Kareen L. K. Coulombe. 2021. 'A
1362 predictive in vitro risk assessment platform for pro-arrhythmic toxicity using
1363 human 3D cardiac microtissues', *Scientific Reports*, 11: 10228.

1364 Kortenkamp, A. 2020. 'Which chemicals should be grouped together for mixture risk
1365 assessments of male reproductive disorders?', *Mol Cell Endocrinol*, 499:
1366 110581.

1367 Kortenkamp, Andreas, Marta Axelstad, Asma H. Baig, Åke Bergman, Carl-Gustaf
1368 Bornehag, Peter Ceniñ, Sofie Christiansen, Barbara Demeneix, Arash
1369 Derakhshan, Jean-Baptiste Fini, Caroline Frädrich, Timo Hamers, Lina Hellwig,
1370 Josef Köhrle, Tim I.M. Korevaar, Johan Lindberg, Olwenn Martin, Marcel E.
1371 Meima, Philipp Mergenthaler, Nikolai Nikolov, David Du Pasquier, Robin P.
1372 Peeters, Bjorn Platzack, Louise Ramhøj, Sylvie Remaud, Kostja Renko, Martin
1373 Scholze, Harald Stachelscheid, Terje Svingen, Fabian Wagenaars, Eva Bay
1374 Wedebye, and R. Thomas Zoeller. 2020. 'Removing Critical Gaps in Chemical
1375 Test Methods by Developing New Assays for the Identification of Thyroid
1376 Hormone System-Disrupting Chemicals—The ATHENA Project', *International
1377 Journal of Molecular Sciences*, 21: 3123.

1378 Kortenkamp, Andreas, and Michael Faust. 2018. 'Regulate to reduce chemical mixture
1379 risk', *Science*, 361: 224-26.

1380 Koster, S, MH Bani-Estivals, M Bonuomo, E Bradley, MC Chagnon, ML Garcia, F
1381 Godts, T Gude, R Helling, P Paseiro-Losada, G Pieper, M Rennen, T Simat, and
1382 L Spack. 2015. "Guidance on best practices on the risk assessment of non-
1383 intentionally added substances (NIAS) in food contact materials and articles."
1384 In.: ILSI Europe.

1385 Koster, Sander, Monique Rennen, Winfried Leeman, Geert Houben, Bas Muilwijk,
1386 Frederique van Acker, and Lisette Krul. 2013. 'A novel safety assessment
1387 strategy for non-intentionally added substances (NIAS) in carton food contact
1388 materials', *Food Additives & Contaminants: Part A*, 31: 422-43.

1389 Krewski, Daniel, Michael Bird, Mustafa Al-Zoughool, Nicholas Birkett, Mélissa
1390 Billard, Brittany Milton, Jerry M. Rice, Yann Grosse, Vincent J. Cogliano, Mark
1391 A. Hill, Robert A. Baan, Julian Little, and Jan M. Zielinski. 2019. 'Key

1392 characteristics of 86 agents known to cause cancer in humans', *Journal of*
1393 *Toxicology and Environmental Health, Part B*, 22: 244-63.

1394 Krishna, S., B. Berridge, and N. Kleinstreuer. 2021. 'High-Throughput Screening to
1395 Identify Chemical Cardiotoxic Potential', *Chem Res Toxicol*, 34: 566-83.

1396 Küblbeck, Jenni, Taina Vuorio, Jonna Niskanen, Vittorio Fortino, Albert Braeuning,
1397 Khaled Abass, Arja Rautio, Jukka Hakkola, Paavo Honkakoski, and Anna-Liisa
1398 Levonen. 2020. 'The EDCMET Project: Metabolic Effects of Endocrine
1399 Disruptors', *International Journal of Molecular Sciences*, 21: 3021.

1400 La Merrill, Michele A., Laura N. Vandenberg, Martyn T. Smith, William Goodson,
1401 Patience Browne, Heather B. Patisaul, Kathryn Z. Guyton, Andreas
1402 Kortenkamp, Vincent J. Cogliano, Tracey J. Woodruff, Linda Rieswijk, Hideko
1403 Sone, Kenneth S. Korach, Andrea C. Gore, Lauren Zeise, and R. Thomas
1404 Zoeller. 2020. 'Consensus on the key characteristics of endocrine-disrupting
1405 chemicals as a basis for hazard identification', *Nature Reviews Endocrinology*,
1406 16: 45-57.

1407 Lane, J. M., J. R. Doyle, J. P. Fortin, A. S. Kopin, and J. M. Ordovás. 2014.
1408 'Development of an OP9 derived cell line as a robust model to rapidly study
1409 adipocyte differentiation', *PLoS One*, 9: e112123.

1410 Larsson-Nyrén, G., J. Sehlin, P. Rorsman, and E. Renström. 2001. 'Perchlorate
1411 stimulates insulin secretion by shifting the gating of L-type Ca²⁺ currents in
1412 mouse pancreatic B-cells towards negative potentials', *Pflugers Arch*, 441: 587-
1413 95.

1414 Leeman, Winfried, and Lisette Krul. 2015. 'Non-intentionally added substances in food
1415 contact materials: how to ensure consumer safety', *Current Opinion in Food*
1416 *Science*, 6: 33-37.

1417 Legler, Juliette, Daniel Zalko, Fabien Jourdan, Miriam Jacobs, Bernard Fromenty,
1418 Patrick Balaguer, William Bourguet, Vesna Munic Kos, Angel Nadal, Claire
1419 Beausoleil, Susana Cristobal, Sylvie Remy, Sibylle Ermler, Luigi Margiotta-
1420 Casaluci, Julian L. Griffin, Bruce Blumberg, Christophe Chesné, Sebastian
1421 Hoffmann, Patrik L. Andersson, and Jorke H. Kamstra. 2020. 'The GOLIATH
1422 Project: Towards an Internationally Harmonised Approach for Testing
1423 Metabolism Disrupting Compounds', *International Journal of Molecular*
1424 *Sciences*, 21: 3480.

- 1425 Levine, H., N. Jørgensen, A. Martino-Andrade, J. Mendiola, D. Weksler-Derri, I.
1426 Mindlis, R. Pinotti, and S. H. Swan. 2017. 'Temporal trends in sperm count: a
1427 systematic review and meta-regression analysis', *Hum Reprod Update*, 23: 646-
1428 59.
- 1429 Levine, Hagai, Niels Jørgensen, Anderson Martino-Andrade, Jaime Mendiola, Dan
1430 Weksler-Derri, Maya Jolles, Rachel Pinotti, and Shanna H Swan. 2022.
1431 'Temporal trends in sperm count: a systematic review and meta-regression
1432 analysis of samples collected globally in the 20th and 21st centuries', *Human
1433 Reproduction Update*, 29: 157-76.
- 1434 Li, J., L. Zheng, X. Wang, K. Yao, L. Shi, X. Sun, G. Yang, L. Jiang, C. Zhang, Y.
1435 Wang, L. Jiang, and X. Liu. 2019. 'Taurine protects INS-1 cells from apoptosis
1436 induced by Di(2-ethylhexyl) phthalate via reducing oxidative stress and
1437 autophagy', *Toxicol Mech Methods*, 29: 445-56.
- 1438 Li, N., G. D. Papandonatos, A. M. Calafat, K. Yolton, B. P. Lanphear, A. Chen, and J.
1439 M. Braun. 2020. 'Gestational and childhood exposure to phthalates and child
1440 behavior', *Environ Int*, 144: 106036.
- 1441 Lind, Lars, Jesus A. Araujo, Aaron Barchowsky, Scott Belcher, Brian R. Berridge,
1442 Nipavan Chiamvimonvat, Weihsueh A. Chiu, Vincent J. Cogliano, Sarah
1443 Elmore, Aimen K. Farraj, Aldrin V. Gomes, Cliona M. McHale, Kathleen B.
1444 Meyer-Tamaki, Nikki Gillum Posnack, Hugo M. Vargas, Xi Yang, Lauren
1445 Zeise, Changcheng Zhou, and Martyn T. Smith. 2021. 'Key Characteristics of
1446 Cardiovascular Toxicants', *Environ Health Perspect*, 129: 095001.
- 1447 Liu, P., F. Yang, Y. Wang, and Z. Yuan. 2018. 'Perfluorooctanoic Acid (PFOA)
1448 Exposure in Early Life Increases Risk of Childhood Adiposity: A Meta-Analysis
1449 of Prospective Cohort Studies', *Int J Environ Res Public Health*, 15.
- 1450 Liu, Qicai. 2021. 'Effects of Environmental Endocrine-Disrupting Chemicals on Female
1451 Reproductive Health.' in Huidong Zhang and Jie Yan (eds.), *Environment and
1452 Female Reproductive Health* (Springer Singapore: Singapore).
- 1453 Liu, Wang, Jiye Zhang, Xuefang Liang, Yuchen Wang, Ruimin Liu, Ruiqing Zhang,
1454 Jinmiao Zha, and Christopher J. Martyniuk. 2022. 'Environmental
1455 concentrations of 2, 4-DTBP cause immunotoxicity in zebrafish (*Danio rerio*)
1456 and may elicit ecological risk to wildlife', *Chemosphere*, 308: 136465.

1457 Lizarraga, L. E., G. W. Suter, J. C. Lambert, G. Patlewicz, J. Q. Zhao, J. L. Dean, and P.
1458 Kaiser. 2023. 'Advancing the science of a read-across framework for evaluation
1459 of data-poor chemicals incorporating systematic and new approach methods',
1460 *Regul Toxicol Pharmacol*, 137: 105293.

1461 Loganathan, Neruja, Ashkan Salehi, Jennifer A Chalmers, and Denise D Belsham.
1462 2018. 'Bisphenol A Alters Bmal1, Per2, and Rev-Erba mRNA and Requires
1463 Bmal1 to Increase Neuropeptide Y Expression in Hypothalamic Neurons',
1464 *Endocrinology*, 160: 181-92.

1465 Luderer, Ulrike, Brenda Eskenazi, Russ Hauser, Kenneth S. Korach, Cliona M. McHale,
1466 Francisco Moran, Linda Rieswijk, Gina Solomon, Osamu Udagawa, Luoping
1467 Zhang, Marya Zlatnik, Lauren Zeise, and Martyn T. Smith. 2019. 'Proposed Key
1468 Characteristics of Female Reproductive Toxicants as an Approach for
1469 Organizing and Evaluating Mechanistic Data in Hazard Assessment', *Environ*
1470 *Health Perspect*, 127: 075001.

1471 Luebke, R. 2012. 'Immunotoxicant screening and prioritization in the twenty-first
1472 century', *Toxicol Pathol*, 40: 294-9.

1473 Madia, Federica, Andrew Worth, Maurice Whelan, and Raffaella Corvi. 2019.
1474 'Carcinogenicity assessment: Addressing the challenges of cancer and chemicals
1475 in the environment', *Environ Int*, 128: 417-29.

1476 Maffini, M. V., L. Trasande, and T. G. Neltner. 2016. 'Perchlorate and Diet: Human
1477 Exposures, Risks, and Mitigation Strategies', *Curr Environ Health Rep*, 3: 107-
1478 17.

1479 Maffini, Maricel V., Heather M. Alger, Erik D. Olson, and Thomas G. Neltner. 2013.
1480 'Looking Back to Look Forward: A Review of FDA's Food Additives Safety
1481 Assessment', *COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD*
1482 *SAFETY*, 12.

1483 Maffini, Maricel V., Ana M. Soto, Janine M. Calabro, Angelo A. Ucci, and Carlos
1484 Sonnenschein. 2004. 'The stroma as a crucial target in rat mammary gland
1485 carcinogenesis', *Journal of Cell Science*, 117: 1495-502.

1486 Mahalingam, S., L. Ther, L. Gao, W. Wang, A. Ziv-Gal, and J. A. Flaws. 2017. 'The
1487 effects of in utero bisphenol A exposure on ovarian follicle numbers and
1488 steroidogenesis in the F1 and F2 generations of mice', *Reprod Toxicol*, 74: 150-
1489 57.

1490 Manikkam, M., R. Tracey, C. Guerrero-Bosagna, and M. K. Skinner. 2013. 'Plastics
1491 derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic
1492 transgenerational inheritance of obesity, reproductive disease and sperm
1493 epimutations', *PLoS One*, 8: e55387.

1494 Maoz, Ben M. 2021. 'Brain-on-a-Chip: Characterizing the next generation of advanced
1495 in vitro platforms for modeling the central nervous system', *APL
1496 Bioengineering*, 5: 030902.

1497 Mariana, Melissa, Joana Feiteiro, Ignacio Verde, and Elisa Cairrao. 2016. 'The effects
1498 of phthalates in the cardiovascular and reproductive systems: A review', *Environ
1499 Int*, 94: 758-76.

1500 Marroqui, L., J. Martinez-Pinna, M. Castellano-Muñoz, R. S. Dos Santos, R. M.
1501 Medina-Gali, S. Soriano, I. Quesada, J. A. Gustafsson, J. A. Encinar, and A.
1502 Nadal. 2021. 'Bisphenol-S and Bisphenol-F alter mouse pancreatic β -cell ion
1503 channel expression and activity and insulin release through an estrogen receptor
1504 ER β mediated pathway', *Chemosphere*, 265: 129051.

1505 Martínez-Ibarra, A., L. D. Martínez-Razo, K. MacDonald-Ramos, M. Morales-Pacheco,
1506 E. R. Vázquez-Martínez, M. López-López, M. Rodríguez Dorantes, and M.
1507 Cerbón. 2021. 'Multisystemic alterations in humans induced by bisphenol A and
1508 phthalates: Experimental, epidemiological and clinical studies reveal the need to
1509 change health policies', *Environmental Pollution*, 271: 116380.

1510 Martinez-Pinna, J., L. Marroqui, A. Hmadcha, J. Lopez-Beas, S. Soriano, S. Villar-
1511 Pazos, P. Alonso-Magdalena, R. S. Dos Santos, I. Quesada, F. Martin, B. Soria,
1512 JÅ Gustafsson, and A. Nadal. 2019. 'Oestrogen receptor β mediates the actions
1513 of bisphenol-A on ion channel expression in mouse pancreatic beta cells',
1514 *Diabetologia*, 62: 1667-80.

1515 Marty, Sue, Manon Beekhuijzen, Alex Charlton, Nina Hallmark, Bethany R. Hannas,
1516 Sylvia Jacobi, Stephanie Melching-Kollmuss, Ursula G. Sauer, Larry P. Sheets,
1517 Volker Strauss, Daniel Urbisch, Philip A. Botham, and Bennard van
1518 Ravenzwaay. 2021. 'Towards a science-based testing strategy to identify
1519 maternal thyroid hormone imbalance and neurodevelopmental effects in the
1520 progeny – part II: how can key events of relevant adverse outcome pathways be
1521 addressed in toxicological assessments?', *Critical Reviews in Toxicology*, 51:
1522 328-58.

- 1523 Marvel, Skylar W., Kimberly To, Fabian A. Grimm, Fred A. Wright, Ivan Rusyn, and
1524 David M. Reif. 2018. 'ToxPi Graphical User Interface 2.0: Dynamic exploration,
1525 visualization, and sharing of integrated data models', *BMC Bioinformatics*, 19:
1526 80.
- 1527 McDonough, Callie M., Hannah Shibo Xu, and Tai L. Guo. 2021. 'Toxicity of bisphenol
1528 analogues on the reproductive, nervous, and immune systems, and their
1529 relationships to gut microbiome and metabolism: insights from a multi-species
1530 comparison', *Critical Reviews in Toxicology*, 51: 283-300.
- 1531 Melnick, R. L. 2001. 'Is peroxisome proliferation an obligatory precursor step in the
1532 carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?', *Environ Health
1533 Perspect*, 109: 437-42.
- 1534 Messerlian, C., I. Souter, A. J. Gaskins, P. L. Williams, J. B. Ford, Y. H. Chiu, A. M.
1535 Calafat, and R. Hauser. 2016. 'Urinary phthalate metabolites and ovarian reserve
1536 among women seeking infertility care', *Hum Reprod*, 31: 75-83.
- 1537 Midya, Vishal, Elena Colicino, David V. Conti, Kiros Berhane, Erika Garcia, Nikos
1538 Stratakis, Sandra Andrusaityte, Xavier Basagaña, Maribel Casas, Serena Fossati,
1539 Regina Gražulevičienė, Line Småstuen Haug, Barbara Heude, Léa Maitre,
1540 Rosemary McEachan, Eleni Papadopoulou, Theano Roumeliotaki, Claire
1541 Philippat, Cathrine Thomsen, Jose Urquiza, Marina Vafeiadi, Nerea Varo,
1542 Miriam B. Vos, John Wright, Rob McConnell, Martine Vrijheid, Lida Chatzi,
1543 and Damaskini Valvi. 2022. 'Association of Prenatal Exposure to Endocrine-
1544 Disrupting Chemicals With Liver Injury in Children', *JAMA Network Open*, 5:
1545 e2220176-e76.
- 1546 Minet, Laura, Zhanyun Wang, Anna Shalin, Thomas A. Bruton, Arlene Blum, Graham
1547 F. Peaslee, Heather Schwartz-Narbonne, Marta Venier, Heather Whitehead, Yan
1548 Wu, and Miriam L. Diamond. 2022. 'Use and release of per- and polyfluoroalkyl
1549 substances (PFASs) in consumer food packaging in U.S. and Canada',
1550 *Environmental Science: Processes & Impacts*, 24: 2032-42.
- 1551 Mohajer, N., C. Y. Du, C. Checkcinco, and B. Blumberg. 2021. 'Obesogens: How They
1552 Are Identified and Molecular Mechanisms Underlying Their Action', *Front
1553 Endocrinol (Lausanne)*, 12: 780888.
- 1554 Mohanto, Nayan Chandra, Yuki Ito, Sayaka Kato, and Michihiro Kamijima. 2021.
1555 'Life-Time Environmental Chemical Exposure and Obesity: Review of

1556 Epidemiological Studies Using Human Biomonitoring Methods', *Frontiers in*
1557 *Endocrinology*, 12.

1558 Moon, Shinje, Sung Hoon Yu, Chang Beom Lee, Young Joo Park, Hyung Joon Yoo,
1559 and Dong Sun Kim. 2021. 'Effects of bisphenol A on cardiovascular disease: An
1560 epidemiological study using National Health and Nutrition Examination Survey
1561 2003–2016 and meta-analysis', *Science of The Total Environment*, 763: 142941.

1562 Moore, Sonja, Laura Paalanen, Lisa Melymuk, Andromachi Katsonouri, Marike
1563 Kolossa-Gehring, and Hanna Tolonen. 2022. 'The Association between ADHD
1564 and Environmental Chemicals—A Scoping Review', *International*
1565 *Journal of Environmental Research and Public Health*, 19: 2849.

1566 Muncke, J. 2009. 'Exposure to endocrine disrupting compounds via the food chain: Is
1567 packaging a relevant source?', *Sci Total Environ*, 407: 4549-59.

1568 Muncke, J., T. Backhaus, B. Geueke, M. V. Maffini, O. V. Martin, J. P. Myers, A. M.
1569 Soto, L. Trasande, X. Trier, and M. Scheringer. 2017. 'Scientific challenges in
1570 the risk assessment of food contact materials', *Environ Health Perspect*, 125:
1571 095001.

1572 Muncke, Jane. 2021. 'Tackling the toxics in plastics packaging', *PLOS Biology*, 19:
1573 e3000961.

1574 Muncke, Jane, Anna-Maria Andersson, Thomas Backhaus, Justin M. Boucher, Bethanie
1575 Carney Almroth, Arturo Castillo Castillo, Jonathan Chevrier, Barbara A.
1576 Demeneix, Jorge A. Emmanuel, Jean-Baptiste Fini, David Gee, Birgit Geueke,
1577 Ksenia Groh, Jerrold J. Heindel, Jane Houlihan, Christopher D. Kassotis, Carol
1578 F. Kwiatkowski, Lisa Y. Lefferts, Maricel V. Maffini, Olwenn V. Martin, John
1579 Peterson Myers, Angel Nadal, Cristina Nerin, Katherine E. Pelch, Seth Rojello
1580 Fernández, Robert M. Sargis, Ana M. Soto, Leonardo Trasande, Laura N.
1581 Vandenberg, Martin Wagner, Changqing Wu, R. Thomas Zoeller, and Martin
1582 Scheringer. 2020. 'Impacts of food contact chemicals on human health: a
1583 consensus statement', *Environmental Health*, 19: 25.

1584 Mustieles, Vicente, and Mariana F. Fernández. 2020. 'Bisphenol A shapes children's
1585 brain and behavior: towards an integrated neurotoxicity assessment including
1586 human data', *Environmental Health*, 19: 66.

1587 Naderi, Mohammad, and Raymond W. M. Kwong. 2020. 'A comprehensive review of
1588 the neurobehavioral effects of bisphenol S and the mechanisms of action: New
1589 insights from in vitro and in vivo models', *Environ Int*, 145: 106078.

1590 Naidenko, Olga V., David Q. Andrews, Alexis M. Temkin, Tasha Stoiber, Uloma Igara
1591 Uche, Sydney Evans, and Sean Perrone-Gray. 2021. 'Investigating Molecular
1592 Mechanisms of Immunotoxicity and the Utility of ToxCast for Immunotoxicity
1593 Screening of Chemicals Added to Food', *International Journal of Environmental
1594 Research and Public Health*, 18: 3332.

1595 Naxerova, Kamila. 2021. 'Mutation fingerprints encode cellular histories', *Nature*, 597:
1596 334-36.

1597 Neale, P. A., B. I. Escher, M. L. de Baat, J. Enault, and F. D. L. Leusch. 2023. 'Effect-
1598 Based Trigger Values Are Essential for the Uptake of Effect-Based Methods in
1599 Water Safety Planning', *Environ Toxicol Chem*, 42: 714-26.

1600 Neltner, Thomas G., Heather M. Alger, Jack E. Leonard, and Maricel V. Maffini.
1601 2013a. 'Data Gaps in Toxicity Testing of Chemicals Allowed in Food in the
1602 United States', *Reproductive Toxicology*.

1603 ———. 2013b. 'Data gaps in toxicity testing of chemicals allowed in food in the United
1604 States', *Reproductive Toxicology*, 42: 85-94.

1605 Nerin, C., P. Alfaro, M. Aznar, and C. Domeño. 2013. 'The challenge of identifying
1606 non-intentionally added substances from food packaging materials: A review',
1607 *Analytica Chimica Acta*, 775: 14-24.

1608 Nerin, C., and E. Asensio. 2007. 'Migration of organic compounds from a multilayer
1609 plastic-paper material intended for food packaging', *Analytical and
1610 Bioanalytical Chemistry*, 389: 589-96.

1611 Nerín, C., Q. Z. Su, P. Vera, N. Mendoza, and R. Ausejo. 2020. 'Influence of
1612 nonylphenol from multilayer plastic films on artificial insemination of sows',
1613 *Anal Bioanal Chem*, 412: 6519-28.

1614 Nerin, C., J. L. Ubeda, P. Alfaro, Y. Dahmani, M. Aznar, E. Canellas, and R. Ausejo.
1615 2014. 'Compounds from multilayer plastic bags cause reproductive failures in
1616 artificial insemination', *Sci. Rep.*, 4.

1617 Nerín, Cristina, Siméon Bourdoux, Birgit Faust, Thomas Gude, Céline Lesueur,
1618 Thomas Simat, Angela Stoermer, Els Van Hoek, and Peter Oldring. 2022.
1619 'Guidance in selecting analytical techniques for identification and quantification

1620 of non-intentionally added substances (NIAS) in food contact materials
1621 (FCMS)', *Food Additives & Contaminants: Part A*, 39: 620-43.

1622 Nerin, Cristina, Elena Canellas, Paula Vera, Estefanía Garcia-Calvo, José Luis Luque-
1623 Garcia, Carmen Cámara, Raquel Ausejo, Joaquín Miguel, and Noelia Mendoza.
1624 2018. 'A common surfactant used in food packaging found to be toxic for
1625 reproduction in mammals', *Food and Chemical Toxicology*, 113: 115-24.

1626 Nicholson, L. B. 2016. 'The immune system', *Essays Biochem*, 60: 275-301.

1627 Nowak, Karolina, Ewa Jabłońska, and Wioletta Ratajczak-Wrona. 2019.
1628 'Immunomodulatory effects of synthetic endocrine disrupting chemicals on the
1629 development and functions of human immune cells', *Environ Int*, 125: 350-64.

1630 NTP. 2018. "Report on Carcinogens. Monograph on Antimony Trioxide." In *RoC*
1631 *Monograph*, edited by National Toxicology Program. U.S. Department of Health
1632 and Human Services.

1633 ———. 2021. 'RoC Review of Antimony Trioxide', U.S. Department of Health and
1634 Human Services, Accessed 23 Dec 2022.
1635 [https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/completed/antimonyt/
1636 index.html](https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/completed/antimonyt/index.html).

1637 Obsekov, Vladislav, Linda G. Kahn, and Leonardo Trasande. 2022. 'Leveraging
1638 Systematic Reviews to Explore Disease Burden and Costs of Per- and
1639 Polyfluoroalkyl Substance Exposures in the United States', *Exposure and
1640 Health*.

1641 OECD. 2015. "Guidance Document on Revisions to OECD Genetic Toxicology Test
1642 Guidelines." In, edited by Organisation for Economic Co-operation and
1643 Development.

1644 ———. 2022. 'OECD Test Guidelines for Chemicals', Accessed 23 Dec 2022.
1645 [https://www.oecd.org/chemicalsafety/testing/oecdguidelinesforhetestingofchem
1646 icals.htm](https://www.oecd.org/chemicalsafety/testing/oecdguidelinesforhetestingofchemicals.htm).

1647 Ogungbesan, Adejoke, April Neal-Kluever, and Penny Rice. 2019. 'Exploring the use of
1648 current immunological assays for the developmental immunotoxicity assessment
1649 of food contact materials', *Food and Chemical Toxicology*, 133: 110801.

1650 Oldring, P. K. T., L. Castle, C. O'Mahony, and J. Dixon. 2014. 'Estimates of dietary
1651 exposure to bisphenol A (BPA) from light metal packaging using food
1652 consumption and packaging usage data: a refined deterministic approach and a

1653 fully probabilistic (FACET) approach', *Food Additives & Contaminants: Part A*,
1654 31: 466-89.

1655 Oldring, Peter, Birgit Faust, Thomas Gude, Céline Lesueur, Thomas Simat, Angela
1656 Stoermer, Els Van Hoek, and Cristina Nerin. 2023. "An Overview of
1657 Approaches for Analysing NIAS from different FCMs." In, edited by ILSI
1658 Europe. Zenodo: ILSI Europe.

1659 Omer, Elsa, Emmanuelle Bichon, Sébastien Hutinet, Anne-Lise Royer, Fabrice
1660 Monteau, Hélène Germon, Paul Hill, Gérald Remaud, Gaud Dervilly-Pinel,
1661 Ronan Cariou, and Bruno Le Bizec. 2019. 'Toward the characterisation of non-
1662 intentionally added substances migrating from polyester-polyurethane lacquers
1663 by comprehensive gas chromatography-mass spectrometry technologies',
1664 *Journal of Chromatography A*, 1601: 327-34.

1665 Pant, J., P. Ranjan, and S. B. Deshpande. 2011. 'Bisphenol A decreases atrial
1666 contractility involving NO-dependent G-cyclase signaling pathway', *J Appl*
1667 *Toxicol*, 31: 698-702.

1668 Park, S., J. M. Lee, J. W. Kim, J. H. Cheong, H. J. Yun, Y. C. Hong, Y. Kim, D. H.
1669 Han, H. J. Yoo, M. S. Shin, S. C. Cho, and B. N. Kim. 2015. 'Association
1670 between phthalates and externalizing behaviors and cortical thickness in children
1671 with attention deficit hyperactivity disorder', *Psychol Med*, 45: 1601-12.

1672 Park, Sunghee Estelle, Jinchul Ahn, Hyo-Eun Jeong, Inchan Youn, Dongeun Huh, and
1673 Seok Chung. 2021. 'A three-dimensional in vitro model of the peripheral
1674 nervous system', *NPG Asia Materials*, 13: 2.

1675 Parng, Chuenlei, Nicole Marie Roy, Christopher Ton, Yingxin Lin, and Patricia
1676 McGrath. 2007. 'Neurotoxicity assessment using zebrafish', *Journal of*
1677 *Pharmacological and Toxicological Methods*, 55: 103-12.

1678 Pérez-Bermejo, M., I. Mas-Pérez, and M. T. Murillo-Llorente. 2021. 'The Role of the
1679 Bisphenol A in Diabetes and Obesity', *Biomedicines*, 9.

1680 Piekarski, D. J., K. R. Diaz, and M. W. McNerney. 2020. 'Perfluoroalkyl chemicals in
1681 neurological health and disease: Human concerns and animal models',
1682 *NeuroToxicology*, 77: 155-68.

1683 Pieke, E. N., K. Granby, X. Trier, and J. Smedsgaard. 2017. 'A framework to estimate
1684 concentrations of potentially unknown substances by semi-quantification in

1685 liquid chromatography electrospray ionization mass spectrometry', *Analytica*
1686 *Chimica Acta*, 975: 30-41.

1687 Pierozan, P., F. Jernerren, and O. Karlsson. 2018. 'Perfluorooctanoic acid (PFOA)
1688 exposure promotes proliferation, migration and invasion potential in human
1689 breast epithelial cells', *Arch Toxicol*, 92: 1729-39.

1690 Pillai, Hari K., Mingliang Fang, Dmitri Beglov, Dima Kozakov, Sandor Vajda, Heather
1691 M. Stapleton, Thomas F. Webster, and Jennifer J. Schlezinger. 2014. 'Ligand
1692 Binding and Activation of PPAR γ by Firemaster® 550: Effects on Adipogenesis
1693 and Osteogenesis *in Vitro*', *Environ Health Perspect*, 122: 1225-32.

1694 Pinter, E., B. Rainer, T. Czerny, E. Riegel, B. Schilter, M. Marin-Kuan, and M. Tacker.
1695 2020. 'Evaluation of the Suitability of Mammalian In Vitro Assays to Assess the
1696 Genotoxic Potential of Food Contact Materials', *Foods*, 9.

1697 Pinto, C. L., K. Markey, D. Dix, and P. Browne. 2018. 'Identification of candidate
1698 reference chemicals for in vitro steroidogenesis assays', *Toxicol In Vitro*, 47:
1699 103-19.

1700 Poças, M. F. F., J. C. Oliveira, H. J. Pinto, M. E. Zacarias, and T. Hogg. 2009.
1701 'Characterization of patterns of food packaging usage in Portuguese homes',
1702 *Food Addit. Contam., Part A* 26: 1314-24.

1703 Pouech, Charlène, Agneta Kiss, Florent Lafay, Didier Léonard, Laure Wiest, Cécile
1704 Cren-Olivé, and Emmanuelle Vulliet. 2015. 'Human exposure assessment to a
1705 large set of polymer additives through the analysis of urine by solid phase
1706 extraction followed by ultra high performance liquid chromatography coupled to
1707 tandem mass spectrometry', *J Chromatogr A*, 1423: 111-23.

1708 Predieri, Barbara, Patrizia Bruzzi, Elena Bigi, Silvia Ciancia, Simona F. Madeo, Laura
1709 Lucaccioni, and Lorenzo Iughetti. 2020. 'Endocrine Disrupting Chemicals and
1710 Type 1 Diabetes', *International Journal of Molecular Sciences*, 21: 2937.

1711 Prins, G. S., W. Y. Hu, G. B. Shi, D. P. Hu, S. Majumdar, G. Li, K. Huang, J. L. Nelles,
1712 S. M. Ho, C. L. Walker, A. Kajdacsy-Balla, and R. B. van Breemen. 2014.
1713 'Bisphenol A promotes human prostate stem-progenitor cell self-renewal and
1714 increases in vivo carcinogenesis in human prostate epithelium', *Endocrinology*,
1715 155: 805-17.

1716 Qian, Shasha, Hanxu Ji, XiaoXiao Wu, Ning Li, Yang Yang, Jiangtao Bu, Xiaoming
1717 Zhang, Ling Qiao, Henglin Yu, Ning Xu, and Chi Zhang. 2018. 'Detection and

1718 quantification analysis of chemical migrants in plastic food contact products',
1719 *PLoS One*, 13: e0208467.

1720 Qin, Wei-Ping, Lin-Ying Cao, Chuan-Hai Li, Liang-Hong Guo, John Colbourne, and
1721 Xiao-Min Ren. 2020. 'Perfluoroalkyl Substances Stimulate Insulin Secretion by
1722 Islet β Cells via G Protein-Coupled Receptor 40', *Environmental Science &*
1723 *Technology*, 54: 3428-36.

1724 Radke, Elizabeth G., Joseph M. Braun, John D. Meeker, and Glinda S. Cooper. 2018.
1725 'Phthalate exposure and male reproductive outcomes: A systematic review of the
1726 human epidemiological evidence', *Environ Int*, 121: 764-93.

1727 Radke, Elizabeth G., Joseph M. Braun, Rebecca M. Nachman, and Glinda S. Cooper.
1728 2020. 'Phthalate exposure and neurodevelopment: A systematic review and
1729 meta-analysis of human epidemiological evidence', *Environ Int*, 137: 105408.

1730 Rajkumar, Abishankari, Trang Luu, Marc A. Beal, Tara S. Barton-Maclaren, Barbara F.
1731 Hales, and Bernard Robaire. 2022. 'Phthalates and alternative plasticizers
1732 differentially affect phenotypic parameters in gonadal somatic and germ cell
1733 lines†', *Biology of Reproduction*, 106: 613-27.

1734 Ramadan, Manelle, Blake Cooper, and Nikki Gillum Posnack. 2020. 'Bisphenols and
1735 phthalates: Plastic chemical exposures can contribute to adverse cardiovascular
1736 health outcomes', *Birth Defects Research*, 112: 1362-85.

1737 Rancière, Fanny, Jasmine G. Lyons, Venurs H.Y. Loh, Jérémie Botton, Tamara
1738 Galloway, Tiange Wang, Jonathan E. Shaw, and Dianna J. Magliano. 2015.
1739 'Bisphenol A and the risk of cardiometabolic disorders: a systematic review with
1740 meta-analysis of the epidemiological evidence', *Environmental Health*, 14: 1-23.

1741 Rebolledo-Solleiro, Daniela, Laura Y Castillo Flores, and Helena Solleiro-
1742 Villavicencio. 2021. 'Impact of BPA on behavior, neurodevelopment and
1743 neurodegeneration', *FBL*, 26: 363-400.

1744 Rericha, Yvonne, Lisa Truong, Connor Leong, Dunping Cao, Jennifer A. Field, and
1745 Robyn L. Tanguay. 2022. 'Dietary Perfluorohexanoic Acid (PFHxA) Exposures
1746 in Juvenile Zebrafish Produce Subtle Behavioral Effects across Generations',
1747 *Toxics*, 10: 372.

1748 Ribeiro, C. M., B. T. S. Beserra, N. G. Silva, C. L. Lima, P. R. S. Rocha, M. S. Coelho,
1749 F. A. R. Neves, and A. A. Amato. 2020. 'Exposure to endocrine-disrupting

1750 chemicals and anthropometric measures of obesity: a systematic review and
1751 meta-analysis', *BMJ Open*, 10: e033509.

1752 Richard, A. M., R. S. Judson, K. A. Houck, C. M. Grulke, P. Volarath, I.
1753 Thillainadarajah, C. Yang, J. Rathman, M. T. Martin, J. F. Wambaugh, T. B.
1754 Knudsen, J. Kancherla, K. Mansouri, G. Patlewicz, A. J. Williams, S. B. Little,
1755 K. M. Crofton, and R. S. Thomas. 2016. 'ToxCast Chemical Landscape: Paving
1756 the Road to 21st Century Toxicology', *Chem Res Toxicol*, 29: 1225-51.

1757 Rider, Cynthia V., Cliona M. McHale, Thomas F. Webster, Leroy Lowe, William H.
1758 Goodson, Michele A. La Merrill, Glenn Rice, Lauren Zeise, Luoping Zhang, and
1759 Martyn T. Smith. 2021. 'Using the Key Characteristics of Carcinogens to
1760 Develop Research on Chemical Mixtures and Cancer', *Environ Health Perspect*,
1761 129: 035003.

1762 Robitaille, J., N. D. Denslow, B. I. Escher, H. G. Kurita-Oyamada, V. Marlatt, C. J.
1763 Martyniuk, L. Navarro-Martín, R. Prosser, T. Sanderson, V. Yargeau, and V. S.
1764 Langlois. 2022. 'Towards regulation of Endocrine Disrupting chemicals (EDCs)
1765 in water resources using bioassays - A guide to developing a testing strategy',
1766 *Environ Res*, 205: 112483.

1767 Rojas-Rueda, David, Emily Morales-Zamora, Wael Abdullah Alsufyani, Christopher H.
1768 Herbst, Salem M. AlBalawi, Reem Alsukait, and Mashael Alomran. 2021.
1769 'Environmental Risk Factors and Health: An Umbrella Review of Meta-
1770 Analyses', *International Journal of Environmental Research and Public Health*,
1771 18: 704.

1772 Rønnev-Jessen, L, and MJ Bissell. 2009. 'Breast cancer by proxy: can the
1773 microenvironment be both the cause and consequence? ', *Trends Mol Med.*, 15:
1774 5-13.

1775 Roser, Max, Hannah Ritchie, and Fiona Spooner. 2021. 'Burden of disease',
1776 OurWorldInData.org, Accessed 23 December 2022.
1777 <https://ourworldindata.org/burden-of-disease>.

1778 Rotenberg Iu, S., V. T. Mazaev, and T. G. Shlepnina. 1978. 'Peculiarities of alkyl tin
1779 effects on respiration and oxidative phosphorylation of rat liver mitochondria',
1780 *Ukr Biokhim Zh (1978)*, 50: 695-700.

1781 Ruan, Yuefei, Dipa Lalwani, Karen Y. Kwok, Eriko Yamazaki, Sachi Taniyasu, Nirmal
1782 J. I. Kumar, Paul K. S. Lam, and Nobuyoshi Yamashita. 2019. 'Assessing

1783 exposure to legacy and emerging per- and polyfluoroalkyl substances via hair –
1784 The first nationwide survey in India', *Chemosphere*, 229: 366-73.

1785 Rudel, Ruthann A., Janet M. Gray, Connie L. Engel, Teresa W. Rawsthorne, Robin E.
1786 Dodson, Janet M. Ackerman, Jeanne Rizzo, Janet L. Nudelman, and Julia Green
1787 Brody. 2011. 'Food Packaging and Bisphenol A and Bis(2-Ethyhexyl) Phthalate
1788 Exposure: Findings from a Dietary Intervention', *Environ Health Perspect*, 119:
1789 914-20.

1790 Rusyn, I., X. Arzuaga, R. C. Cattley, J. C. Corton, S. S. Ferguson, P. Godoy, K. Z.
1791 Guyton, N. Kaplowitz, S. R. Khetani, R. A. Roberts, R. A. Roth, and M. T.
1792 Smith. 2021. 'Key Characteristics of Human Hepatotoxicants as a Basis for
1793 Identification and Characterization of the Causes of Liver Toxicity', *Hepatology*,
1794 74: 3486-96.

1795 Ruszkiewicz, Joanna A., Adi Pinkas, Mahfuzur R. Miah, Rebecca L. Weitz, Michael J.
1796 A. Lawes, Ayodele J. Akinyemi, Omamuyovwi M. Ijomone, and Michael
1797 Aschner. 2018. 'C. elegans as a model in developmental neurotoxicology',
1798 *Toxicology and Applied Pharmacology*, 354: 126-35.

1799 Sachana, M., C. Willett, F. Pistollato, and A. Bal-Price. 2021. 'The potential of
1800 mechanistic information organised within the AOP framework to increase
1801 regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of
1802 assays', *Reprod Toxicol*, 103: 159-70.

1803 Sanchis, Yovana, Vicent Yusà, and Clara Coscollà. 2017. 'Analytical strategies for
1804 organic food packaging contaminants', *Journal of Chromatography A*, 1490: 22-
1805 46.

1806 Sang, C., Y. Song, T. W. Jin, S. Zhang, L. Fu, Y. Zhao, X. Zou, Z. Wang, H. Gao, and
1807 S. Liu. 2021. 'Bisphenol A induces ovarian cancer cell proliferation and
1808 metastasis through estrogen receptor- α pathways', *Environ Sci Pollut Res Int*,
1809 28: 36060-68.

1810 Sant, K. E., H. M. Jacobs, K. A. Borofski, J. B. Moss, and A. R. Timme-Laragy. 2017.
1811 'Embryonic exposures to perfluorooctanesulfonic acid (PFOS) disrupt pancreatic
1812 organogenesis in the zebrafish, *Danio rerio*', *Environ Pollut*, 220: 807-17.

1813 Sapozhnikova, Yelena, Alberto Nuñez, and John Johnston. 2021. 'Screening of
1814 chemicals migrating from plastic food contact materials for oven and microwave

1815 applications by liquid and gas chromatography - Orbitrap mass spectrometry',
1816 *Journal of Chromatography A*, 1651: 462261.

1817 Scholz, Stefan, Werner Brack, Beate I. Escher, Jörg Hackermüller, Matthias Liess,
1818 Martin von Bergen, Lukas Y. Wick, Ana C. Zenclussen, and Rolf Altenburger.
1819 2022. 'The EU chemicals strategy for sustainability: an opportunity to develop
1820 new approaches for hazard and risk assessment', *Archives of Toxicology*, 96:
1821 2381-86.

1822 Schug, T. T., R. Abagyan, B. Blumberg, T. J. Collins, D. Crews, P. L. DeFur, S. M.
1823 Dickerson, T. M. Edwards, A. C. Gore, L. J. Guillette, T. Hayes, J. J. Heindel,
1824 A. Moores, H. B. Patisaul, T. L. Tal, K. A. Thayer, L. N. Vandenberg, J. C.
1825 Warner, C. S. Watson, F. S. vom Saal, R. T. Zoeller, K. P. O'Brien, and J. P.
1826 Myers. 2013. 'Designing endocrine disruption out of the next generation of
1827 chemicals', *Green Chemistry*.

1828 Seo, Y., T. H. Shin, and H. S. Kim. 2019. 'Current Strategies to Enhance Adipose Stem
1829 Cell Function: An Update', *Int J Mol Sci*, 20.

1830 Serras, Ana S., Joana S. Rodrigues, Madalena Cipriano, Armanda V. Rodrigues, Nuno
1831 G. Oliveira, and Joana P. Miranda. 2021. 'A Critical Perspective on 3D Liver
1832 Models for Drug Metabolism and Toxicology Studies', *Frontiers in Cell and
1833 Developmental Biology*, 9.

1834 Severin, Isabelle, Emilie Souton, Laurence Dahbi, and Marie Christine Chagnon. 2017.
1835 'Use of bioassays to assess hazard of food contact material extracts: State of the
1836 art', *Food and Chemical Toxicology*, 105: 429-47.

1837 Shaffer, R. M., K. K. Ferguson, L. Sheppard, T. James-Todd, S. Butts, S.
1838 Chandrasekaran, S. H. Swan, E. S. Barrett, R. Nguyen, N. Bush, T. F. McElrath,
1839 and S. Sathyanarayana. 2019. 'Maternal urinary phthalate metabolites in relation
1840 to gestational diabetes and glucose intolerance during pregnancy', *Environ Int*,
1841 123: 588-96.

1842 Sharma, Aditi, Josephine Mollier, Richard W. K. Brocklesby, Charlotte Caves, Channa
1843 N. Jayasena, and Suks Minhas. 2020. 'Endocrine-disrupting chemicals and male
1844 reproductive health', *Reproductive Medicine and Biology*, 19: 243-53.

1845 Shoucri, B. M., V. T. Hung, R. Chamorro-García, T. Shioda, and B. Blumberg. 2018.
1846 'Retinoid X Receptor Activation During Adipogenesis of Female Mesenchymal
1847 Stem Cells Programs a Dysfunctional Adipocyte', *Endocrinology*, 159: 2863-83.

1848 Silva, M. J., A. R. Slakman, J. A. Reidy, J. L. Preau, Jr., A. R. Herbert, E. Samandar, L.
1849 L. Needham, and A. M. Calafat. 2004. 'Analysis of human urine for fifteen
1850 phthalate metabolites using automated solid-phase extraction', *J Chromatogr B*
1851 *Analyt Technol Biomed Life Sci*, 805: 161-7.

1852 Skakkebaek, N. E., E. Rajpert-De Meyts, G. M. Buck Louis, J. Toppari, A. M.
1853 Andersson, M. L. Eisenberg, T. K. Jensen, N. Jørgensen, S. H. Swan, K. J.
1854 Sapra, S. Ziebe, L. Priskorn, and A. Juul. 2016. 'Male Reproductive Disorders
1855 and Fertility Trends: Influences of Environment and Genetic Susceptibility',
1856 *Physiol Rev*, 96: 55-97.

1857 Skakkebaek, N. E., E. Rajpert-De Meyts, and K. M. Main. 2001. 'Testicular dysgenesis
1858 syndrome: an increasingly common developmental disorder with environmental
1859 aspects: Opinion', *Human Reproduction*, 16: 972-78.

1860 Skakkebaek, Niels E., Rune Lindahl-Jacobsen, Hagai Levine, Anna-Maria Andersson,
1861 Niels Jørgensen, Katharina M. Main, Øjvind Lidegaard, Lærke Priskorn, Stine
1862 A. Holmboe, Elvira V. Bräuner, Kristian Almstrup, Luiz R. Franca, Ariana
1863 Znaor, Andreas Kortenkamp, Roger J. Hart, and Anders Juul. 2022.
1864 'Environmental factors in declining human fertility', *Nature Reviews*
1865 *Endocrinology*, 18: 139-57.

1866 Smith, M. T., K. Z. Guyton, C. F. Gibbons, J. M. Fritz, C. J. Portier, I. Rusyn, D. M.
1867 DeMarini, J. C. Caldwell, R. J. Kavlock, P. F. Lambert, S. S. Hecht, J. R.
1868 Bucher, B. W. Stewart, R. A. Baan, V. J. Coglianò, and K. Straif. 2016. 'Key
1869 Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of
1870 Carcinogenesis', *Environ Health Perspect*, 124: 713-21.

1871 Soave, I., T. Occhiali, C. Assorgi, R. Marci, and D. Caserta. 2020. 'Environmental toxin
1872 exposure in polycystic ovary syndrome women and possible ovarian neoplastic
1873 repercussion', *Curr Med Res Opin*, 36: 693-703.

1874 Sonnenschein, Carlos, and Ana M. Soto. 2020. 'Over a century of cancer research:
1875 Inconvenient truths and promising leads', *PLOS Biology*, 18: e3000670.

1876 Soto, A.M., C. Brisken, C.M. Schaeberle, and C Sonnenschein. 2013. 'Does cancer start
1877 in the womb? Altered mammary gland development and predisposition to breast
1878 cancer due to in utero exposure to endocrine disruptors.', *J Mammary Gland Biol*
1879 *Neoplasia*, 18: 199-208.

1880 Souton, Emilie, Isabelle Severin, Ludovic Le Hegarat, Kevin Hogeveen, Abdulhadi
1881 Aljawish, Valérie Fessard, and Chagnon Marie-Christine. 2017. 'Genotoxic
1882 effects of food contact recycled paperboard extracts on two human hepatic cell
1883 lines', *Food Additives & Contaminants: Part A*: 1-12.

1884 Stratakis, N., V. Conti D, R. Jin, K. Margetaki, D. Valvi, A. P. Siskos, L. Maitre, E.
1885 Garcia, N. Varo, Y. Zhao, T. Roumeliotaki, M. Vafeiadi, J. Urquiza, S.
1886 Fernández-Barrés, B. Heude, X. Basagana, M. Casas, S. Fossati, R.
1887 Gražulevičienė, S. Andrušaitytė, K. Uppal, R. R. C. McEachan, E.
1888 Papadopoulou, O. Robinson, L. S. Haug, J. Wright, M. B. Vos, H. C. Keun, M.
1889 Vrijheid, K. T. Berhane, R. McConnell, and L. Chatzi. 2020. 'Prenatal Exposure
1890 to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver
1891 Injury in Children', *Hepatology*, 72: 1758-70.

1892 Street, Maria E., Karine Audouze, Juliette Legler, Hideko Sone, and Paola Palanza.
1893 2021. 'Endocrine Disrupting Chemicals: Current Understanding, New Testing
1894 Strategies and Future Research Needs', *International Journal of Molecular
1895 Sciences*, 22: 933.

1896 Stucki, A. O., T. S. Barton-Maclaren, Y. Bhuller, J. E. Henriquez, T. R. Henry, C. Hirn,
1897 J. Miller-Holt, E. G. Nagy, M. M. Perron, D. E. Ratzlaff, T. J. Stedeford, and A.
1898 J. Clippinger. 2022. 'Use of new approach methodologies (NAMs) to meet
1899 regulatory requirements for the assessment of industrial chemicals and pesticides
1900 for effects on human health', *Front Toxicol*, 4: 964553.

1901 Susmann, H. P., L. A. Schaidler, K. M. Rodgers, and R. Rudel. 2019. 'Dietary Habits
1902 Related to Food Packaging and Population Exposure to PFASs', *Environ Health
1903 Perspect*, 127: 10.

1904 Svensson, Katherine, Eva Tanner, Chris Gennings, Christian Lindh, Hannu Kiviranta,
1905 Sverre Wikström, and Carl-Gustaf Bornehag. 2021. 'Prenatal exposures to
1906 mixtures of endocrine disrupting chemicals and children's weight trajectory up
1907 to age 5.5 in the SELMA study', *Scientific Reports*, 11: 11036.

1908 Symeonides, Christos, Manuel Brunner, Yannick Mulders, Priyanka Toshniwal,
1909 Matthew Cantrell, Louise Mofflin, and Sarah Dunlop. 2021. 'Buy-now-pay-later:
1910 Hazards to human and planetary health from plastics production, use and waste',
1911 *Journal of Paediatrics and Child Health*, 57: 1795-804.

- 1912 Tang, Q. Q., T. C. Otto, and M. D. Lane. 2004. 'Commitment of C3H10T1/2 pluripotent
1913 stem cells to the adipocyte lineage', *Proc Natl Acad Sci U S A*, 101: 9607-11.
- 1914 Tanner, Eva M., Maria Unenge Hallerbäck, Sverre Wikström, Christian Lindh, Hannu
1915 Kiviranta, Chris Gennings, and Carl-Gustaf Bornehag. 2020. 'Early prenatal
1916 exposure to suspected endocrine disruptor mixtures is associated with lower IQ
1917 at age seven', *Environ Int*, 134: 105185.
- 1918 Taylor, Raegyn B., and Yelena Sapozhnikova. 2022. 'Assessing Chemical Migration
1919 from Plastic Food Packaging into Food Simulant by Gas and Liquid
1920 Chromatography with High-Resolution Mass Spectrometry', *Journal of
1921 Agricultural and Food Chemistry*, 70: 4805-16.
- 1922 Temkin, Alexis M., Barbara A. Hocevar, David Q. Andrews, Olga V. Naidenko, and
1923 Lisa M. Kamendulis. 2020. 'Application of the Key Characteristics of
1924 Carcinogens to Per and Polyfluoroalkyl Substances', *International Journal of
1925 Environmental Research and Public Health*, 17: 1668.
- 1926 Thurston, S. W., J. Mendiola, A. R. Bellamy, H. Levine, C. Wang, A. Sparks, J. B.
1927 Redmon, E. Z. Drobnis, and S. H. Swan. 2016. 'Phthalate exposure and semen
1928 quality in fertile US men', *Andrology*, 4: 632-8.
- 1929 Tice, R. R., C. P. Austin, R. J. Kavlock, and J. R. Bucher. 2013. 'Improving the human
1930 hazard characterization of chemicals: a Tox21 update', *Environ Health Perspect*,
1931 121: 756-65.
- 1932 Tingaud-Sequeira, Angèle, Nafia Ouadah, and Patrick J. Babin. 2011. 'Zebrafish
1933 obesogenic test: a tool for screening molecules that target adiposity', *Journal of
1934 Lipid Research*, 52: 1765-72.
- 1935 Tisler, Selina, and Jan H. Christensen. 2022. 'Non-target screening for the identification
1936 of migrating compounds from reusable plastic bottles into drinking water',
1937 *Journal of Hazardous Materials*, 429: 128331.
- 1938 Tolosa, Laia, Nuria Jiménez, Gabriela Pérez, José V. Castell, M. José Gómez-Lechón,
1939 and M. Teresa Donato. 2018. 'Customised in vitro model to detect human
1940 metabolism-dependent idiosyncratic drug-induced liver injury', *Archives of
1941 Toxicology*, 92: 383-99.
- 1942 Trasande, L., R. T. Zoeller, U. Hass, A. Kortenkamp, P. Grandjean, J. P. Myers, J.
1943 DiGangi, M. Bellanger, R. Hauser, J. Legler, N. E. Skakkebaek, and J. J.
1944 Heindel. 2015. 'Estimating burden and disease costs of exposure to endocrine-

1945 disrupting chemicals in the European union', *J Clin Endocrinol Metab*, 100:
1946 1245-55.

1947 Trasande, L., R. T. Zoeller, U. Hass, A. Kortenkamp, P. Grandjean, J. P. Myers, J.
1948 DiGangi, P. M. Hunt, R. Rudel, S. Sathyanarayana, M. Bellanger, R. Hauser, J.
1949 Legler, N. E. Skakkebaek, and J. J. Heindel. 2016. 'Burden of disease and costs
1950 of exposure to endocrine disrupting chemicals in the European Union: an
1951 updated analysis', *Andrology*, 4: 565-72.

1952 Trier, Xenia, Kit Granby, and Jan Christensen. 2011. 'Polyfluorinated surfactants (PFS)
1953 in paper and board coatings for food packaging', *Environmental Science and
1954 Pollution Research*: 1-13.

1955 Tsochatzis, Emmanouil D., Joao Alberto Lopes, Helen Gika, Trine Kastrup Dalsgaard,
1956 and Georgios Theodoridis. 2021. 'A fast SALLE GC–MS/MS multi-analyte
1957 method for the determination of 75 food packaging substances in food
1958 simulants', *Food Chemistry*, 361: 129998.

1959 Turner, P. A., B. Gurumurthy, J. L. Bailey, C. M. Elks, and A. V. Janorkar. 2017.
1960 'Adipogenic Differentiation of Human Adipose-Derived Stem Cells Grown as
1961 Spheroids', *Process Biochem*, 59: 312-20.

1962 Van Bossuyt, M., E. Van Hoeck, T. Vanhaecke, V. Rogiers, and B. Mertens. 2016.
1963 'Printed paper and board food contact materials as a potential source of food
1964 contamination', *Regulatory Toxicology and Pharmacology*, 81: 10-19.

1965 ———. 2017. 'Safeguarding human health using in silico tools?', *Archives of
1966 Toxicology*, 91: 2705-06.

1967 ———. 2019. 'Prioritizing Substances of Genotoxic Concern for In-Depth Safety
1968 Evaluation Using Non-Animal Approaches: The Example of Food Contact
1969 Materials', *Altex-Alternatives to Animal Experimentation*, 36: 215-30.

1970 van den Dries, M. A., M. Guxens, S. Spaan, K. K. Ferguson, E. Philips, S. Santos, V.
1971 W. V. Jaddoe, A. Ghassabian, L. Trasande, H. Tiemeier, and A. Pronk. 2020.
1972 'Phthalate and Bisphenol Exposure during Pregnancy and Offspring Nonverbal
1973 IQ', *Environ Health Perspect*, 128: 77009.

1974 Vessa, B., B. Perlman, P. G. McGovern, and S. S. Morelli. 2022a. 'Endocrine disruptors
1975 and female fertility: a review of pesticide and plasticizer effects', *F S Rep*, 3: 86-
1976 90.

- 1977 Vessa, Blake, Barry Perlman, Peter G. McGovern, and Sara S. Morelli. 2022b.
- 1978 'Endocrine disruptors and female fertility: a review of pesticide and plasticizer
- 1979 effects', *F&S Reports*, 3: 86-90.
- 1980 Villar-Pazos, S., J. Martinez-Pinna, M. Castellano-Muñoz, P. Alonso-Magdalena, L.
- 1981 Marroqui, I. Quesada, J. A. Gustafsson, and A. Nadal. 2017. 'Molecular
- 1982 mechanisms involved in the non-monotonic effect of bisphenol-a on ca²⁺ entry
- 1983 in mouse pancreatic β -cells', *Sci Rep*, 7: 11770.
- 1984 Völker, Johannes, Felicity Ashcroft, Åsa Vedøy, Lisa Zimmermann, and Martin
- 1985 Wagner. 2022. 'Adipogenic Activity of Chemicals Used in Plastic Consumer
- 1986 Products', *Environmental Science & Technology*, 56: 2487-96.
- 1987 Walker, Vickie R., Abee L. Boyles, Katherine E. Pelch, Stephanie D. Holmgren,
- 1988 Andrew J. Shapiro, Chad R. Blystone, Michael J. Devito, Retha R. Newbold,
- 1989 Robyn Blain, Pamela Hartman, Kristina A. Thayer, and Andrew A. Rooney.
- 1990 2018. 'Human and animal evidence of potential transgenerational inheritance of
- 1991 health effects: An evidence map and state-of-the-science evaluation', *Environ*
- 1992 *Int*, 115: 48-69.
- 1993 Wan, M. L. Y., V. A. Co, and H. El-Nezami. 2022. 'Endocrine disrupting chemicals and
- 1994 breast cancer: a systematic review of epidemiological studies', *Crit Rev Food Sci*
- 1995 *Nutr*, 62: 6549-76.
- 1996 Wang, B., M. Li, Z. Zhao, J. Lu, Y. Chen, Y. Xu, M. Xu, W. Wang, T. Wang, Y. Bi,
- 1997 and G. Ning. 2019. 'Urinary bisphenol A concentration and glucose homeostasis
- 1998 in non-diabetic adults: a repeated-measures, longitudinal study', *Diabetologia*,
- 1999 62: 1591-600.
- 2000 Wang, Dongqi, Haoduo Zhao, Xunchang Fei, Shane Allen Synder, Mingliang Fang, and
- 2001 Min Liu. 2021. 'A comprehensive review on the analytical method, occurrence,
- 2002 transformation and toxicity of a reactive pollutant: BADGE', *Environ Int*, 155:
- 2003 106701.
- 2004 Wang, I. Jen, Chia-Yang Chen, and Carl-Gustaf Bornehag. 2016. 'Bisphenol A
- 2005 exposure may increase the risk of development of atopic disorders in children',
- 2006 *International Journal of Hygiene and Environmental Health*, 219: 311-16.
- 2007 Wang, W., K. S. Hafner, and J. A. Flaws. 2014. 'In utero bisphenol A exposure disrupts
- 2008 germ cell nest breakdown and reduces fertility with age in the mouse', *Toxicol*
- 2009 *Appl Pharmacol*, 276: 157-64.

- 2010 Wang, Z., M. H. Alderman, C. Asgari, and H. S. Taylor. 2020. 'Fetal Bisphenol-A
2011 Induced Changes in Murine Behavior and Brain Gene Expression Persisted in
2012 Adult-aged Offspring', *Endocrinology*, 161.
- 2013 Wassenaar, P. N. H., L. Trasande, and J. Legler. 2017. 'Systematic Review and Meta-
2014 Analysis of Early-Life Exposure to Bisphenol A and Obesity-Related Outcomes
2015 in Rodents', *Environ Health Perspect*, 125: 106001.
- 2016 Wehbe, Zena, Suzanne A. Nasser, Ahmed El-Yazbi, Salam Nasreddine, and Ali H. Eid.
2017 2020. 'Estrogen and Bisphenol A in Hypertension', *Current Hypertension
2018 Reports*, 22: 23.
- 2019 Wen, Zeng-Jin, Zhong-Yu Wang, and Yin-Feng Zhang. 2022. 'Adverse cardiovascular
2020 effects and potential molecular mechanisms of DEHP and its metabolites—A
2021 review', *Science of The Total Environment*, 847: 157443.
- 2022 Westerhoff, P., P. Prapaipong, E. Shock, and A. Hillaireau. 2008. 'Antimony leaching
2023 from polyethylene terephthalate (PET) plastic used for bottled drinking water',
2024 *Water Res*, 42: 551-6.
- 2025 WHO. 2018. 'Noncommunicable diseases. Fact sheet':
2026 <http://www.who.int/mediacentre/factsheets/fs355/en/>.
- 2027 ———. 2020. 'Infertility', WHO, Accessed 23 Dec 2022. [https://www.who.int/news-
2028 room/fact-sheets/detail/infertility](https://www.who.int/news-room/fact-sheets/detail/infertility).
- 2029 ———. 2021. 'Cardiovascular diseases (CVDs)', Accessed 23 Dec 2022.
2030 [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
2031 \(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
- 2032 Williams, David E., Gayle Orner, Kristin D. Willard, Susan Tilton, Jerry D. Hendricks,
2033 Clifford Pereira, Abby D. Benninghoff, and George S. Bailey. 2009. 'Rainbow
2034 Trout (*Oncorhynchus mykiss*) and Ultra-Low Dose Cancer Studies',
2035 *Comparative Biochemistry and Physiology*, 149: 175-81.
- 2036 Willis, RA. 1948. *Pathology of tumors* (Butterworth & Co Ltd: London, England).
- 2037 Wu, W., M. Li, A. Liu, C. Wu, D. Li, Q. Deng, B. Zhang, J. Du, X. Gao, and Y. Hong.
2038 2020. 'Bisphenol A and the Risk of Obesity a Systematic Review With Meta-
2039 Analysis of the Epidemiological Evidence', *Dose Response*, 18:
2040 1559325820916949.
- 2041 Xie, Ming-Yu, Hong Ni, De-Sheng Zhao, Li-Ying Wen, Ke-Sheng Li, Hui-Hui Yang,
2042 Shu-Si Wang, Heng Zhang, and Hong Su. 2016. 'Exposure to bisphenol A and

2043 the development of asthma: A systematic review of cohort studies',
2044 *Reproductive Toxicology*, 65: 224-29.

2045 Yan, Sujuan, Yamei Chen, Min Dong, Weizhong Song, Scott M. Belcher, and Hong-
2046 Sheng Wang. 2011. 'Bisphenol A and 17 β -Estradiol Promote Arrhythmia in the
2047 Female Heart via Alteration of Calcium Handling', *PLoS One*, 6: e25455.

2048 Yang, Shu, Masato Ooka, Ryan Jared Margolis, and Menghang Xia. 2023. 'Liver three-
2049 dimensional cellular models for high-throughput chemical testing', *Cell Reports*
2050 *Methods*, 3: 100432.

2051 Ye, Wenqing, Ernesto H. Ramos, Brian C. Wong, and Denise D. Belsham. 2016.
2052 'Beneficial Effects of Metformin and/or Salicylate on Palmitate- or TNF α -
2053 Induced Neuroinflammatory Marker and Neuropeptide Gene Regulation in
2054 Immortalized NPY/AgRP Neurons', *PLoS One*, 11: e0166973.

2055 Zare Jeddi, Maryam, Nancy B. Hopf, Susana Viegas, Anna Bal Price, Alicia Paini,
2056 Christoph van Thriel, Emilio Benfenati, Sophie Ndaw, Jos Bessems, Peter A.
2057 Behnisch, Gabriele Leng, Radu-Corneliu Duca, Hans Verhagen, Francesco
2058 Cubadda, Lorraine Brennan, Imran Ali, Arthur David, Vicente Mustieles,
2059 Mariana F. Fernandez, Henriqueta Louro, and Robert Pasanen-Kase. 2021.
2060 'Towards a systematic use of effect biomarkers in population and occupational
2061 biomonitoring', *Environ Int*, 146: 106257.

2062 Zhang, Qianqian, Xiaona Li, Xin Liu, Moran Dong, Jianpeng Xiao, Jing Wang, Mengya
2063 Zhou, Yiding Wang, Dan Ning, Wenjun Ma, Wei Zhu, Tao Liu, and Bo Zhang.
2064 2020. 'Association between maternal antimony exposure and risk of gestational
2065 diabetes mellitus: A birth cohort study', *Chemosphere*, 246: 125732.

2066 Zhang, Yin-Feng, Chan Shan, Yu Wang, Li-Li Qian, Dong-Dong Jia, Yi-Fei Zhang,
2067 Xiao-Dan Hao, and Hai-Ming Xu. 2020. 'Cardiovascular toxicity and
2068 mechanism of bisphenol A and emerging risk of bisphenol S', *Science of The*
2069 *Total Environment*, 723: 137952.

2070 Zimmermann, Lisa, Georg Dierkes, Thomas A. Ternes, Carolin Völker, and Martin
2071 Wagner. 2019. 'Benchmarking the in vitro toxicity and chemical composition of
2072 plastic consumer products', *Environmental Science & Technology*.

2073 Zimmermann, Lisa, Martin Scheringer, Birgit Geueke, Justin M. Boucher, Lindsey V.
2074 Parkinson, Ksenia J. Groh, and Jane Muncke. 2022. 'Implementing the EU

2075 Chemicals Strategy for Sustainability: The case of Food Contact Chemicals of
2076 Concern', *Journal of Hazardous Materials*: 129167.
2077 Znaor, Ariana, Niels Erik Skakkebaek, Ewa Rajpert-De Meyts, Tomislav Kuliš,
2078 Mathieu Laversanne, Jason Gurney, Diana Sarfati, Katherine A. McGlynn, and
2079 Freddie Bray. 2022. 'Global patterns in testicular cancer incidence and mortality
2080 in 2020', *International Journal of Cancer*, 151: 692-98.

2081 Table 1. Food contact chemicals (FCCs) associated with non-communicable diseases
 2082 (NCDs) from each of the Six Clusters of Disease (SCOD) (non-exhaustive and non-
 2083 systematic overview of epidemiological studies). Identification of FCCs was based on
 2084 the Food Contact Chemicals database (FCCdb) (Groh et al. 2021) and the database on
 2085 migrating and extractable food contact chemicals (FCCmigex) (Geueke et al. 2022).
 2086 This overview is not a complete list of FCCs that are associated with adverse health
 2087 outcomes. Cancer agents are classified by cancer site (IARC 2022).

Disease Cluster	Example disease	Associated FCC exposure	References
Cancers	Testicular cancer	PFOA	(IARC 2016; ATSDR 2021)
	Kidney cancer	PFOA	(IARC 2016; Melnick 2001)
	Breast cancer	PFOA	(Wan, Co, and El-Nezami 2022)
		Ortho-phthalates	(Wan, Co, and El-Nezami 2022)
Cardiovascular diseases	Cardiovascular diseases: including myocardial infarction, arrhythmias, dilated cardiomyopathy, atherosclerosis, and hypertension	BPA	(Moon et al. 2021; Zhang, Shan, et al. 2020; Wehbe et al. 2020; Ramadan, Cooper, and Posnack 2020)
		Ortho-phthalates	(Fu et al. 2020)
Brain-related disorders	Hypothyroid	BPA	(Rebolledo-Solleiro, Flores, and Solleiro-Villavicencio 2021)
		Ortho-phthalates	(Radke et al. 2020)

		Perchlorate	(Radke et al. 2020)
		PFAS	(Piekarski, Diaz, and McNerney 2020)
Abnormal neurodevelopment		Ortho-phthalates: DEHP, DBP, BBP and DEP	(Eales et al. 2022)
Attention Deficit Hyperactivity Disorder/behavior		Lead, BPA, ortho-phthalates	(Moore et al. 2022; Li et al. 2020; Park et al. 2015)
Lower Intelligence Quotient		Endocrine disrupting chemical (EDC) mixture (Ortho-phthalates)	(Tanner et al. 2020; van den Dries et al. 2020)
Language delay		EDC mixture	(Caporale et al. 2022)
Metabolic and endocrine diseases	Type-1 diabetes	BPA, Ortho-phthalates, PFAS	(Predieri et al. 2020)
	Type-2 diabetes	BPA	(Wang et al. 2019; Ranci�re et al. 2015; Akash, Sabir, and Rehman 2020)
		PFOA	(He et al. 2018)
	Pre-diabetes and diabetes	Ortho-phthalates	(Eales et al. 2022; Radke et al. 2018; Dales, Kauri, and Cakmak 2018)
	Obesity (BMI, waist circumference)	BPA	(Fu et al. 2020; P�rez-Bermejo, Mas-

			Pérez, and Murillo-Llorente 2021; Wu et al. 2020)
		PFAS	(Liu et al. 2018; Geiger et al. 2021)
Childhood Obesity	BPA		(Ribeiro et al. 2020)
	Ortho-phthalates		(Buckley et al. 2016)
Gestational diabetes	Antimony		(Zhang, Li, et al. 2020)
	Ortho-phthalates		(Shaffer et al. 2019)
Non-alcoholic fatty liver disease	EDC mixture		(Midya et al. 2022)
	PFAS		(Stratakis et al. 2020)
Immunological disorders	Immunosuppression	PFAS: PFOS and PFOA	(DeWitt, Blossom, and Schaider 2019)
	Childhood asthma	Ortho-phthalates: DEHP and BBzP	(Eales et al. 2022)
	Kidney damage	Melamine	(Hsieh et al. 2012)
Reproductive disorders	Male infertility	BPA	(Sharma et al. 2020)
		Dibutyl phthalate	(Estill et al. 2019)
	Semen quality	Ortho-phthalates: DBP, BBP, DEHP, and DINP	(Radke et al. 2018; Eales et al. 2022; Thurston et al. 2016)

2088

Female infertility (reduced follicular count)	DEHP	(Messerlian et al. 2016)
--	------	-----------------------------

2089 Table 2. Examples of food contact chemicals (FCCs) that are associated with diseases
 2090 from the Six Clusters of Disease (SCOD) by mechanisms from *in-vitro* and/or *in-vivo*
 2091 studies (not including epidemiological studies). Not a complete list: Select references
 2092 only.

Disease Cluster	Food Contact Chemical	Reference
Cancers	Melamine (CAS 108-78-1)	(IARC 2019)
	Formaldehyde (CAS 50-00-0)	(IARC 2012a)
	Benzidine (CAS 92-87-5)	(IARC 2010)
	4,4'-Diamino-3,3' -	(IARC 2012a)
	Dichlorodiphenylmethane	
	(MOCA) (CAS 101-14-4)	
	Antimony trioxide (CAS 1309-64-4)	(NTP 2018)
	Perfluorooctanoic acid	(Temkin et al. 2020;
(PFOA) (CAS 335-67-1)	Pierozan, Jernerren, and Karlsson 2018; Charazac et al. 2022)	
Di (2-ethylhexyl) phthalate	(Hager, Chen, and Zhao	
(DEHP) (CAS 117-81-7)	2022; IARC 2012b)	
Bisphenol A (BPA) (CAS 80-05-7)	(Sang et al. 2021; Jun et al. 2021; Dhimolea et al. 2014; Prins et al. 2014)	
Cardiovascular diseases	Bisphenol A (BPA) (CAS 80-05-7)	(Pant, Ranjan, and Deshpande 2011; Gao and Wang 2014;

		Kofron et al. 2021; Hyun et al. 2021; Krishna, Berridge, and Kleinstreuer 2021; Cooper and Posnack 2022)
	Triclosan (CAS 3380-34-5)	(Krishna, Berridge, and Kleinstreuer 2021)
	Tributyltin chloride (CAS 1461-22-9)	(Krishna, Berridge, and Kleinstreuer 2021)
	Diethanolamine (CAS 111-42-2)	(Jokinen et al. 2005)
	DEHP	(Mariana et al. 2016)
Brain-related disorders	Perchlorate (CAS 14797-73-0)	(Kirk 2006)
	Ortho-phthalates	(Hlisníková et al. 2021)
	BPA	(McDonough, Xu, and Guo 2021; Wang et al. 2020)
	Bisphenol S (BPS) (CAS 80-09-1)	(Naderi and Kwong 2020; McDonough, Xu, and Guo 2021)
Metabolic diseases	BPA	(Villar-Pazos et al. 2017; Martinez-Pinna et al. 2019; Wassenaar, Trasande, and Legler 2017; Desai et al. 2018a; Manikkam et al. 2013)

	Bisphenol A diglycidyl ether (BADGE) (CAS 1675-54-3)	(Wang et al. 2021)
	Organotins	(Rotenberg Iu, Mazaev, and Shlepnina 1978)
	Perchlorate	(Larsson-Nyrén et al. 2001)
	Perfluorooctanesulfonic acid (PFOS) (CAS 1763-23-1)	(Qin et al. 2020; Sant et al. 2017)
	Bisphenol F (BPF) (CAS 620-92-8)	(Marroqui et al. 2021)
	BPS	(Marroqui et al. 2021)
	2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD; Surfynol) (CAS 126-86-3)	(Garcia-Calvo et al. 2020b; Nerin et al. 2018; Nerin et al. 2014)
	DEHP	(Li et al. 2019; Manikkam et al. 2013)
Immunological disorders	Melamine	(IARC 2019)
	BPA	(McDonough, Xu, and Guo 2021)
	BPF	(McDonough, Xu, and Guo 2021)
	BPS	(McDonough, Xu, and Guo 2021; Nowak, Jabłońska, and Ratajczak-Wrona 2019)


	2,4-di-tert-butylphenol (CAS 96-76-4)	(Liu et al. 2022)
	DEHP	(Nowak, Jabłońska, and Ratajczak-Wrona 2019; Hessel et al. 2015)
Reproductive disorders	BPA	(Liu 2021; Vessa et al. 2022b; Wang, Hafner, and Flaws 2014; Mahalingam et al. 2017)
	BADGE	(Wang et al. 2021; Nerin et al. 2014)
	BPS	(Desmarchais et al. 2020)
	DEHP	(Vessa et al. 2022b; Mariana et al. 2016)



2094

2095 Figure 1: Illustration of the terms *food contact article* (FCA), *food contact*
 2096 *material* (FCM), and *food contact chemical* (FCC). The terms FCA and FCM are often
 2097 used interchangeably, but only FCAs can be considered “finished” while FCMs
 2098 oftentimes will be used in combination with other FCMs to make a finished FCA. The
 2099 term FCC describes any chemical that is present in an FCM or FCA, regardless of
 2100 whether it was intentionally used, or if it is a non-intentionally added substance (NIAS),
 2101 such as an impurity, a reaction by-product, a degradation product, or of other origin
 2102 (e.g., a contaminant from recycling).

2103



2104

2105 Figure 2. Chemical risk assessment for food contact chemicals (FCCs): current

2106 practice. The current approach for assessing the safety of FCCs focuses on testing single

2107 substances that are intentionally used to make FCMs. Only genotoxic carcinogenicity is

2108 currently determined as a human health relevant endpoint. However, many more

2109 chemicals can migrate simultaneously from the finished FCM, including unidentified


2110 compounds that are non-intentionally added substances (NIAS). The migrating mixture

2111 is known as the overall migrate, and it can exert adverse effects (mixture toxicity).

2112 Currently, the assessment of the overall migrate's mixture toxicity is not legally

2113 required.

2114



2115

2116 Figure 3. The Six Clusters of Disease (SCOD) concept comprises non-

2117 communicable diseases (NCDs) that are highly prevalent in the global human


2118 population, of increasing concern and associated with hazardous chemical exposures

2119 that can be clustered by disease type. The SCOD are of major concern for public health

2120 and require novel approaches for prevention, namely the identification of chemical

2121 contributors.

2122



2123

2124

Figure 4. Overview of the current vs. proposed approach to food contact

2125

chemical (FCC) testing. The proposed new approach focuses on testing the overall


2126

migrate (i.e., the human exposure-relevant mixture of all migrating FCCs) for its

2127

potential to contribute to the Six Clusters of Disease (SCOD).

2128



2129

2130 Figure 5. The vision for a novel approach to safety assessment of FCMs and
 2131 food contact articles. Finished food contact articles are tested for their real-life mixture
 2132 of all migrating chemicals (the *overall migrate*, i.e. the mixture of all migrating
 2133 chemicals), using *in-vitro* screening assays. The screening assays are mechanism-based
 2134 and identify the key characteristics, key initiating events, or other mechanisms of action
 2135 of the overall migrate. Screening assays are selected around the Six Clusters of Disease
 2136 (SCOD) concept. For overall migrate displaying positive findings in the in-vitro assays,
 2137 non-targeted chemical analyses are carried out to identify the substances driving the
 2138 overall migrate's toxicity.